BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

TENT COOPERATION TREA

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

Assistant Commissioner for Patents
United States Patent and Trademark Office
Box PCT
Washington, D.C.20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 14 July 2000 (14.07.00)	
International application No. PCT/US99/17678	**Applicant's or agent's file reference** 1579-379
International filing date (day/month/year) 05 August 1999 (05.08.99)	**Priority date** (day/month/year) 06 August 1998 (06.08.98)
Applicant HERSHFIELD, Michael et al	

1. The designated Office is hereby notified of its election made:

[X] in the demand filed with the International Preliminary Examining Authority on:

02 March 2000 (02.03.00)

[ ] in a notice effecting later election filed with the International Bureau on:

2. The election [X] was

[ ] was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO **34, chemin des Colombettes** **1211 Geneva 20, Switzerland**	Authorized officer R. Forax
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

CORRECTED VERSION*

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12N 9/09, 15/00, A61K 38/54, C07H 21/04 — A3

(11) International Publication Number: WO 00/08196

(43) International Publication Date: 17 February 2000 (17.02.00)

(21) International Application Number: PCT/US99/17678

(22) International Filing Date: 5 August 1999 (05.08.99)

(30) Priority Data:
60/095,489 6 August 1998 (06.08.98) US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application
US 60/095,489 (CIP)
Filed on 6 August 1998 (06.08.98)

(71) Applicant *(for all designated States except US)*: DUKE UNIVERSITY [US/US]; 230 North Building, Research Drive, Box 90083, Durham, NC 27708–0083 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: HERSHFIELD, Michael [US/US]; 4019 Bristol Road, Durham, NC (US). KELLY, Susan, J. [US/US]; 8104 Lair Court, Chapel Hill, NC (US).

(74) Agent: SADOFF, B., J.; Nixon & Vanderhye P.C., Suite 800, 1100 North Glebe Road, Arlington, VA 22201–4714 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report:
30 March 2000 (30.03.00)

(54) Title: URATE OXIDASE

(57) Abstract

The present invention relates, in general, to urate oxidase (uricase) proteins and nucleic acid molecules encoding same. In particular, the invention relates to uricase proteins which are particularly useful as, for example, intermediates for making improved modified uricase proteins with reduced immunogenicity and increased bioavailability.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/17678

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :C12N 9/09, 15/00; A61K 38/54; C07H 21/04
US CL :435/189, 320.1, 440; 242/94.3. 94.4, 530/23.2

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/189, 320.1, 440; 242/94.3. 94.4, 530/23.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CHEN, R.H. et al. Properties of two urate oxidases modified by the covalent attachment of poly(ethylene glycol). Biochim. Biophys. Acta. August 1981, Vol. 660, pages 293-298, see entire document.	1-4, 6-8, 10, 12, 14, 16, 17
Y	HERSHFIELD, M.S. et al. Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol. Proc. Natl. Acad. Sci., USA. August 1991, Vol 88, pages 7185-7189, see entire document.	1-4, 6-8, 10, 12, 14, 16, 17

[X] Further documents are listed in the continuation of Box C. [ ] See patent family annex.

*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 06 JANUARY 2000	Date of mailing of the international search report 02FEB 2000
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer BRADLEY S. MAYHEW Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/17678

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	ITO et al. Identification of an amino acid residue involved in the substrate-binding site of rat liver uricase by site-directed mutagenesis. Biochem. Biophys. Res. Commun. August 1992, Vol. 187, pages 101-107, see entire document.	1-4, 6-8, 10, 12, 14, 16, 17
Y	YELDANDI, A.V. et al. Human urate oxidase gene: cloning and partial sequence analysis reveal a stop codon within the fifth exon. Biochem. Biophys. Res. Commun.14 September 1990, Vol. 171, pages 641-646, see entire document.	1-4, 6-8, 10, 12, 14, 16, 17
Y	WU et al. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J. Mol. Evol. January 1992, Vol. 34, pages 78-84, see entire document.	1-4, 6-8, 10, 12, 14, 16, 17
Y	WU et al. Urate oxidase: primary structure and evolutionary implications. Proc. Natl. Acad. Sci., USA. December 1989, Vol. 86, pages 9412-9416, see entire document.	1-4, 6-8, 10, 12, 14, 16, 17
Y	US 4,917,888 A (KATRE et al) 17 April 1990, see entire document.	1-4, 6-8, 10, 12, 14, 16, 17

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/17678

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 5, 9, 11, 13 and 15
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

No CRF has been filed. Since the claims recite SEQ ID Nos, or depend therefrom, the claims are found unsearchable.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/17678

B. FIELDS SEARCHED
Electronic data bases consulted (Name of data base and where practicable terms used):

USPAT, EPO, JPO, DERWENT and MEDLINE
search terms: urate oxidase, uricase, PEG, mutant$, and mutation$, bovine, porcine, baboon

European Patent Office

SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application Number
EP 99 93 8996

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Y,D	CHUA C C ET AL: "Use of polyethylene glycol-modified uricase (PEG - uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma" ANNALS OF INTERNAL MEDICINE, NEW YORK, NY, US, 15 July 1988 (1988-07-15), pages 114-117, XP002125211 ISSN: 0003-4819 * the whole document * ---	1-4,6-8, 10,12, 14,16,17	C12N9/00 C12N9/06 C12N15/00 C12N15/52 C12N15/63 C12N5/10 A61K38/54 A61P19/06 C07H21/04
Y,D	DAVIS S ET AL: "HYPOURICAEMIC EFFECT OF POLYETHYLENEGLYCOL MODIFIED URATE OXIDASE" LANCET THE, LANCET LIMITED. LONDON, GB, 8 August 1981 (1981-08-08), pages 281-283, XP000577404 ISSN: 0140-6736 * the whole document * -----	1-4,6-8, 10,12, 14,16,17	

TECHNICAL FIELDS SEARCHED (Int.Cl.7)

C12N
A61K

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

Place of search	Date of completion of the search	Examiner
MUNICH	14 February 2002	Bassias, I

CATEGORY OF CITED DOCUMENTS

X : particularly relevant if taken alone
Y : particularly relevant if combined with another document of the same category
A : technological background
O : non-written disclosure
P : intermediate document

T : theory or principle underlying the invention
E : earlier patent document, but published on, or after the filing date
D : document cited in the application
L : document cited for other reasons

& : member of the same patent family, corresponding document

EPO FORM 1503 03.82 (P04C04)

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 1579-379	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/US99/17678	International filing date *(day/month/year)* 05 AUGUST 1999	Priority date *(day/month/year)* 06 AUGUST 1998
International Patent Classification (IPC) or national classification and IPC Please See Supplemental Sheet.		
Applicant DUKE UNIVERSITY		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 5 sheets.

   ☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consist of a total of 0 sheets.

3. This report contains indications relating to the following items:

   - I ☒ Basis of the report
   - II ☐ Priority
   - III ☒ Non-establishment of report with regard to novelty, inventive step or industrial applicability
   - IV ☐ Lack of unity of invention
   - V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
   - VI ☐ Certain documents cited
   - VII ☐ Certain defects in the international application
   - VIII ☐ Certain observations on the international application

Date of submission of the demand	Date of completion of this report
02 MARCH 2000	24 AUGUST 2000
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer BRADLEY S. MAYHEW
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

Form PCT/IPEA/409 (cover sheet) (July 1998)★

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US99/17678

I. Basis of the report

1. With regard to the elements of the international application:*

[X] the international application as originally filed

[X] the description:
pages 1-33, as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of

[X] the claims:
pages 34-35, as originally filed
pages NONE, as amended (together with any statement) under Article 19
pages NONE, filed with the demand
pages NONE, filed with the letter of

[X] the drawings:
pages 1-18, as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of

[X] the sequence listing part of the description:
pages 37-49, as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.
These elements were available or furnished to this Authority in the following language _____ which is:

[ ] the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).

[ ] the language of publication of the international application (under Rule 48.3(b)).

[ ] the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

[X] contained in the international application in printed form.

[ ] filed together with the international application in computer readable form.

[ ] furnished subsequently to this Authority in written form.

[ ] furnished subsequently to this Authority in computer readable form.

[ ] The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

[ ] The statement that the information recorded in computer readable form is identical to the writen sequence listing has been furnished.

4. [X] The amendments have resulted in the cancellation of:

[X] the description, pages NONE

[X] the claims, Nos. NONE

[X] the drawings, sheets/~~fig~~ NONE

5. [ ] This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

** Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).*

*** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.*

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US99/17678

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been and will not be examined in respect of:

☐ the entire international application.

☒ claims Nos. 5, 9, 11, 13 and 15

because:

☐ the said international application, or the said claim Nos. _ relate to the following subject matter which does not require international preliminary examination *(specify)*.

☐ the description, claims or drawings *(indicate particular elements below)* or said claims Nos. _ are so unclear that no meaningful opinion could be formed *(specify)*.

☐ the claims, or said claims Nos. _ are so inadequately supported by the description that no meaningful opinion could be formed.

☒ no international search report has been established for said claims Nos. (See Attached).

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US99/17678

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. statement

Novelty (N)	Claims	(Please See supplemental sheet)	YES
	Claims	(Please See supplemental sheet)	NO
Inventive Step (IS)	Claims	(Please See supplemental sheet)	YES
	Claims	(Please See supplemental sheet)	NO
Industrial Applicability (IA)	Claims	(Please See supplemental sheet)	YES
	Claims	(Please See supplemental sheet)	NO

2. citations and explanations (Rule 70.7)

Claims 1-4, 6-8, 10, 12, 14, 16, and 17 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest a protein comprising a recombinant uricase protein of a mammalian species which has been modified to insert one or more lysine residues, polynucleotides encoding said recombinant uricase protein, or methods of making said recombinant uricase protein.

NEW CITATIONS

NONE

Supplemental Box
(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

CLASSIFICATION:
The International Patent Classification (IPC) and/or the National classification are as listed below:
IPC(7): C12N 9/02, 15/00; A61K 38/54; C07H 21/04 and US Cl.: 435/189, 320.1, 440; 242/94.3. 94.4, 530/23.2

III. NON-ESTABLISHMENT OF REPORT:

No international search report has been established for claim numbers 5, 9, 11, 13 and 15 .

V. 1. REASONED STATEMENTS:
The report as to Novelty was positive (YES) with respect to claims 1-4, 6-8, 10, 12, 14, 16, and 17.
The report as to Novelty was negative (NO) with respect to claims NONE.
The report as to Inventive Step was positive (YES) with respect to claims 1-4, 6-8, 10, 12, 14, 16, and 17.
The report as to Inventive Step was negative (NO) with respect to claims NONE.
The report as to Industrial Applicability was positive (YES) with respect to claims 1-4, 6-8, 10, 12, 14, 16, and 17.
The report as to Industrial Applicability was negative (NO) with respect to claims NONE.

M·H

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
C12N 9/09, 15/00, A61K 38/54, C07H 21/04

A2

(11) International Publication Number: **WO 00/08196**

(43) International Publication Date: 17 February 2000 (17.02.00)

(21) International Application Number: PCT/US99/17678

(22) International Filing Date: 5 August 1999 (05.08.99)

(30) Priority Data:
60/095,489 6 August 1998 (06.08.98) US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application
US 60/095,489 (CIP)
Filed on 6 August 1998 (06.08.98)

(71) Applicant *(for all designated States except US)*: DUKE UNIVERSITY [US/US]; 230 North Building, Research Drive, Box 90083, Durham, NC 27708–0083 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: HERSHFIELD, Michael [US/US]; 4019 Bristol Road, Durham, NC (US). KELLY, Susan, J. [US/US]; 8104 Lair Court, Chapel Hill, NC (US).

(74) Agent: SADOFF, B., J.; Nixon & Vanderhye P.C., Suite 800, 1100 North Glebe Road, Arlington, VA 22201–4714 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: URATE OXIDASE

(57) Abstract

The present invention relates, in general, to urate oxidase (uricase) proteins and nucleic acid molecules encoding same. In particular, the invention relates to uricase proteins which are particularly useful as, for example, intermediates for making improved modified uricase proteins with reduced immunogenicity and increased bioavailability.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

URATE OXIDASE

The present application claims benefit of U.S. Provisional Application No. 60/095,489, filed August 6, 1998, the entire contents of which is incorporated herein by reference.

The invention disclosed herein was made with U.S. Government support under Grant No. DK48529, awarded by the National Institutes of Health. The Government has certian rights in the invention.

The present invention relates, in general, to urate oxidase (uricase) proteins and nucleic acid molecules encoding same. In particular, the invention relates to uricase proteins which are particularly useful as, for example, intermediates for making improved modified uricase proteins with reduced immunogenicity and increased bioavailability. The preferred modified uricase proteins of the present invention include the uricase proteins covalently bound to poly(ethylene glycols) or poly(ethylene oxides). The present invention provides, therefore, uricase proteins, antibodies which specifically bind with the proteins, nucleic acid molecules enoding the uricase proteins and useful fragments thereof, vectors containing the nucleic acid molecules, host cells containing the vectors and methods of using and making the uricase proteins and nucleic acid molecules.

Background

Gout is the most common inflammatory joint disease in men over age 40 (Roubenoff 1990). Painful gouty arthritis occurs when an elevated blood level of uric acid (*hyperuricemia*) leads to the episodic formation of microscopic crystals of monosodium urate monohydrate in joints. Over time, chronic hyperuricemia can also result in destructive crystalline urate deposits (*tophi*) around joints, in soft tissues, and in some organs (Hershfield 1996). Uric acid has limited solubility in urine and when overexcreted (*hyperuricosuria*) can cause kidney stones (*uricolithiasis*). In patients with certain malignancies, particularly leukemia and lymphoma, marked hyperuricemia and hyperuricosuria (due to enhanced tumor cell turnover and lysis during chemotherapy) pose a serious risk of acute, obstructive renal failure (Sandberg et al. 1956; Gold and Fritz 1957; Cohen et al. 1980; Jones et al. 1990). Severe hyperuricemia and gout are associated with renal dysfunction from various causes, including cyclosporine therapy to

prevent organ allograft rejection (West et al. 1987; Venkataseshan et al. 1990; Ahn et al. 1992; Delaney et al. 1992; George and Mandell 1995).

Hyperuricemia can result from both urate overproduction and underexcretion (Hershfield and Seegmiller 1976; Kelley et al. 1989; Becker and Roessler 1995). When mild, hyperuricemia can be controlled with diet, but when pronounced and associated with serious clinical consequences, it requires treatment with drugs, either a uricosuric agent that promotes uric acid excretion (ineffective if renal function is reduced), or the xanthine oxidase inhibitor allopurinol, which blocks urate formation. Allopurinol is the mainstay of therapy in patients with tophaceous gout, renal insufficiency, leukemia, and some inherited disorders. Treatment for hyperuricemia is generally effective and well-tolerated. However, some patients with disfiguring, incapacitating tophaceous gout are refractory to all conventional therapy (Becker 1988; Fam 1990; Rosenthal and Ryan 1995). Moreover, ~2% of patients treated with allopurinol develop allergic reactions, and a severe hypersensitivity syndrome occurs in ~0.4% (Singer and Wallace 1986; Arellano and Sacristan 1993). This often life-threatening syndrome can cause acute renal and hepatic failure, and severe skin injury (toxic epidermal necrolysis, exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome). Allopurinol also interferes with the metabolism of azathioprine and 6-mercaptopurine, drugs used in the treatment of leukemia and for prevention of organ allograft rejection, conditions in which marked hyperuricemia occurs and may cause severe gout or threaten renal function.

Ultimately, hyperuricemia is the result of mutational inactivation of the human gene for urate oxidase (uricase) during evoultion (Wu et al. 1989; Wu et al. 1992). Active uricase in liver peroxisomes of most non-human primates and other mammals converts urate to allantoin (+ CO_2 and H_2O_2), which is 80-100 times more soluble than uric acid and is handled more efficiently by the kidney. Parenteral uricase, prepared from *Aspergillus flavus* (Uricozyme®, Clin-Midy, Paris), has been used to treat severe hyperuricemia associated with leukemia chemotherapy for over 20 years in France and Italy (London and Hudson 1957; Kissel et al. 1968; Brogard et al. 1972; Kissel et al. 1972; Potaux et al. 1975; Zittoun et al. 1976; Brogard et al. 1978; Masera et al. 1982), and has been used in recent clinical trials in leukemia patients in the US (Pui et al.

1997). Uricase has a more rapid onset of action than allopurinol (Masera et al. 1982; Pui et al. 1997). In patients with gout, uricase infusions can interrupt acute attacks and decrease the size of tophi (Kissel et al. 1968; Potaux et al. 1975; Brogard et al. 1978).

Though effective for treating acute hyperuricemia during a short course of chemotherapy, daily infusion of *A. flavus* uricase would be a serious drawback for treating recurrent or tophaceous gout. In addition, efficacy of *A. flavus* uricase diminishes quickly in patients who develop anti-uricase antibodies (Kissel et al. 1968; Brogard et al. 1978; Escudier et al. 1984; Mourad et al. 1984; Sibony et al. 1984). Serious allergic reactions, including anaphylaxis, have occurred (Donadio et al. 1981; Montagnac and Schillinger 1990; Pui et al. 1997). A longer-acting, less immunogenic preparation of uricase is clearly needed for chronic therapy.

One approach for sequestering exogenous enzymes from proteases and the immune system involves covalent attachment of the inert, nontoxic polymer, monomethoxypolyethylene glycol (PEG) to the surface of proteins (Harris and Zalipsky 1997). Use of PEGs with Mr ~1,000 to >10,000 was first shown to prolong the circulating life and reduce the immunogenicity of several foreign proteins in animals (Abuchowski et al. 1977a; Abuchowski et al. 1977b; Davis et al. 1981a; Abuchowski et al. 1984; Davis et al. 1991). In 1990, bovine adenosine deaminase (ADA) modified with PEG of Mr 5000 (PEG-ADA, ADAGEN®, produced by Enzon, Inc.) became the first PEGylated protein to be approved by the United States Food and Drug Administration, for treatment of severe combined immune deficiency disease due to ADA deficiency (Hershfield et al. 1987). Experience over the past 12 years has shown that anti-ADA antibodies can be detected by a sensitive ELISA in most patients during chronic treatment with PEG-ADA, but there have been no allergic or hypersensitivity reactions; accelerated clearance of PEG-ADA has occurred in a few anti-ADA antibody producing patients, but this has usually been a transient effect (Chaffee et al. 1992; Hershfield 1997). It should be appreciated that immune function of patients with ADA deficiency usually does not become normal during treatment with PEG-ADA (Hershfield 1995; Hershfield and Mitchell 1995). Thus, immunogenicity might be a more significant problem in developing a PEGylated enzyme for chronic treatment of patients with normal immune function.

Immunogenicity will be understood by one of ordinary skill as relating to the induction of an immune response by an injected preparation of an antigen (such as PEG-modified protein or unmodified protein), while antigenicity refers to the reaction of an antigen with preexisting antibodies. Collectively, antigenicity and immunogenicity are referred to as immunoreactivity. In previous studies of PEG-uricase, immunoreactivity was assessed by a variety of methods, including: the reaction *in vitro* of PEG-uricase with preformed antibodies; measurements of induced antibody synthesis; and accelerated clearance rates after repeated injections.

PEGylation has been shown to reduce the immunogenicity and prolong the circulating life of fungal and porcine uricases in animals (Chen et al. 1981; Savoca et al. 1984; Tsuji et al. 1985; Veronese et al. 1997). PEG-modified *Candida* uricase rapidly lowered serum urate to undetectable levels in 5 normouricemic human volunteers (Davis et al. 1981b) . PEGylated *Arthrobacter* uricase produced by Enzon, Inc. was used on a compassionate basis to treat an allopurinol-hypersensitive patient with lymphoma, who presented with renal failure and marked hyperuricemia (Chua et al. 1988; Greenberg and Hershfield 1989). Four intramuscular injections were administered over about two weeks. During this brief period, hyperuricemia was controlled and no anti-uricase antibody could be detected by ELISA in the patient's plasma. Further use and clinical development of this preparation has not been pursued.

To date, no form of uricase or PEG-uricase has been developed that has a suitably long circulating life and sufficiently reduced immunogenicity for safe and reliable use in chronic therapy. The aim of this invention is to provide an improved form of uricase that, in combination with PEGylation, can meet these requirements. The invention is a unique recombinant uricase of mammalian derivation, which has been modified by mutation in a manner that has been shown to enhance the ability of PEGylation to mask potentially immunogenic eptiopes.

Summary of the Invention

It is a general object of the present invention to provide novel uricase proteins and nucleic acid sequences encoding same.

It is another object of the present invention to provide a method of purifying recombinantly produced uricase proteins, such as those described herein.

It is a further object of the present invention to provide a method of reducing the amount of uric acid in a body fluid of a mammal by administering a composition containing a uricase protein of the present invention to the mammal.

It is yet another object of the present invention to provide antibodies to the uricase proteins described herein.

It is another object of the present invention to provide vectors and host cells containing the nucleic acid sequences described herein and methods of using same to produce the uricase proteins coded by same.

The present invention provides uricase proteins which may be used to produce a substantially non-immunogenic PEG-uricase that retains all or nearly all of the uricolytic activity of the unmodified enzyme. Uricolytic activity is expressed herein in International Units (IU) per mg protein wherein an IU of uricase activity is defined as the amount of enzyme which consumes one micromole of uric acid per minute.

The present invention provides a recombinant uricase protein of a mammalian species which has been modified to insert one or more lysine residues. Recombinant protein, as used herein, refers to any artificially produced protein and is distinguished from naturally produced proteins (i.e., that are produced in tissues of an animal that possesses only the natural gene for the specific protein of interest). Protein includes peptides and amino acid sequences. The recombinant uricase protein of the present invention may be a chimera or hybrid of two or more mammalian proteins, peptides or amino acid sequences. In one embodiment, the present invention can be used to prepare a recombinant uricase protein of a mammalian species, which protein has been modified to increase the number of lysines to the point where, after PEGylation of the recombinant uricase protein, the PEGylated uricase product is substantially as enzymatically active as the unmodifed uricase and the PEGylated uricase product is not unacceptably immunogenic. Truncated forms of the uricases of the present invention are also contemplated wherein amino and/or carboxy terminal ends of the uricase may not be present. Preferably, the uricase is not truncated to the extent that lysines are removed.

One of ordinary skill will appreciate that the conjugated uricase-carrier complex must not contain so many linkages as to substantially reduce the enzymatic activity of the uricase or too few linkages so as to remain unacceptably immunogenic. Preferably, the conjugate will retain at least about 70% to about 90% of the uricolytic activity of the unmodified uricase protein while being more stable, such that it retains its enzymatic activity on storage, in mammalian plasma and/or serum at physiological temperature, as compared to the unmodified uricase protein. Retention of at least about 80% to about 85% of the uricolytic activity would be acceptable. Moreover, in a preferred embodiment, the conjugate provides a substantially reduced immunogenicity and/or immunoreactivity than the unmodified uricase protein. In one embodiment, the present invention provides a uricase protein described herein which can be modified by attachment to a non-toxic, non-immunogenic, pharmaceutically acceptable carrier, such as PEG, by covalent linkage to at least 1 of the lysines contained in the uricase protein. Alternatively, the uricase protein is modified by covalent attachment to a carrier through less than about 10 lysines of its amino acid sequence. Attachment to any of 2, 3, 4, 5, 6, 7, 8, or 9 of the lysines are contemplated as alternative embodiments.

The uricase protein of the present invention is a recombinant molecule which includes segments of porcine and baboon liver uricase proteins. A modified baboon sequence is also provided. In one embodiment, the present invention provides a chimeric pig-baboon uricase (PBC uricase (SEQ ID NO:2)) which includes amino acids (aa) 1-225 of porcine uricase (SEQ ID NO:7) and aa 226-304 of baboon uricase (SEQ ID NO:6) (see also sequence in Figure 5). In another embodiment, the present invention provides a chimeric pig-baboon uricase (PKS uricase) which includes aa 1-288 of porcine uricase and aa 289-304 of baboon uricase (SEQ ID NO: 4). Truncated derivates of PBC and PKS are also contemplated. Preferred truncated forms are PBC and PKS proteins truncated to delete either the 6 amino terminal amino acids or the 3 carboxy terminal amino acids, or both. Representative sequences are given in SEQ ID NO:s 8 (PBC amino truncated), 9 (PBC carboxy truncated), 10 (PKS amino truncated) and 11 (PKS carboxy truncated). Each of the PBC uricase, PKS uricase and their truncated forms have one to four more lysines than are found in other mammalian uricases that have been cloned.

The present invention provides nucleic acid (DNA and RNA) molecules (sequences), including isolated, purified and/or cloned forms of the nucleic acid molecules, which code for the uricase proteins and truncated proteins described herein. Preferred embodiments are shown in SEQ ID NO:1 (PBC uricase) and SEQ ID NO:3 (PKS uricase).

Vectors (expression and cloning) including these nucleic acid molecules are also provided by the present invention.

Moreover, the present invention provides host cells containing these vectors.

Antibodies which specifically bind to the uricase proteins of the present invention are also provided. Antibodies to the amino portion to the pig uricase and antibodies to the carboxy portion of baboon uricase, when used in conjunction, should be useful in detecting PBC, or other similar chimeric proteins. Preferably, the antibody to the amino portion of the chimeric uricase should not recognize the amino portion of the baboon uricase and similarly, the antibody to the carboxy portion of the chimeric uricase should not recognize the carboxy portion of the pig uricase. More preferably, antibodies are provided which specifically bind PBC or PKS but do not bind the native proteins, such as pig and/or baboon uricases.

In another embodiment, the present invention can be used to prepare a pharmaceutical composition for reducing the amount of uric acid in body fluids, such as urine and/or serum or plasma, containing at least one of the uricase proteins or uricase conjugates described herein and a pharmaceutically acceptable carrier, diluent or excipient.

The present invention also may be used in a method for reducing the amount of uric acid in body fluids of a mammal. The method includes administering to a mammal an uric acid-lowering effective amount of a composition containing a uricase protein or uricase conjugate of the present invention and a diluent, carrier or excipient, which is preferably a pharmaceutically acceptable carrier, diluent or excipient. The mammal to be treated is preferably a human.

The administering step may be, for example, injection by intravenous, intradermal, subcutaneous, intramuscular or intraperitoneal routes. The elevated uric acid levels may be in blood or urine, and may be associated with gout, tophi, renal insufficiency, organ transplantation or malignant disease.

In another embodiment, the present invention provides a method for isolating and or purifying a uricase from a solution of uricase containing, for example, cellular and subcellular debris from, for example, a recombinant production process. Preferably, the method of purification takes advantage of the limited solubility of mammalian uricase at low pH (Conley et al. 1979), by washing the crude recombinant extract at a pH of about 7 to about 8.5 to remove a majority of the proteins that are soluble at this low pH range, whereafter active uricase is solubilized in a buffer, preferably sodium carbonate buffer, at a pH of about 10-11, preferably about 10.2. The solubilized active uricase may then be applied to an anion exchange column, such as a Q Sepharose column, which is washed with low to high salt gradient in a buffer at a pH of about 8.5, after which purified uricase is obtained by eluting with a sodium chloride gradient in sodium carbonate buffer at a pH of about 10 to about 11, preferably about 10.2. The enzyme may be further purified by gel filtration chromatography at a pH of about 10 to about 11. At this stage, the enzyme may be further purified by lowering the pH to about 8.5 or less to selectively precipitate uricase, but not more soluble contaminates. After washing at low pH (7-8) the uricase is then solubilized at a pH of about 10.2. The uricase preparation could then be analyzed by methods known in the art of pharmaceutical preparation, such as, for example, any one of high performance liquid chromatography (HPLC), other chromatographic methods, light scattering, centrifugation and/or gel electrophoresis.

Brief Description of the Drawings

Figure 1. SDS-mercaptoethanol PAGE (12% gel) analysis

Figure 2. Circulating life of native and PEGylated PBC uricase.

Figure 3. Relationship of serum uricase activity to the serum and urine concentrations of uric acid.

Figure 4. Maintenance of circulating level of uricase activity (measured in serum) after repeated injection.

Figure 5 shows the deduced amino acid sequences of pig-baboon chimeric uricase (PBC uricase) and porcine uricase containing the mutations R291K and T301S (PKS uricase), compared with the porcine and baboon sequences.

Figure 6. Comparison of amino acid sequences PKS and pig uricase.

Figure 7. Comparison of amino acid sequences of PBC and PKS.

Figure 8. Comparison of amino acid sequences of PBC and pig uricase.

Figure 9. Comparison of amino acid sequence of pig uricase and D3H.

Figure 10. Comparison of amino acid sequences of PBC and and D3H.

Figure 11-1 and 11-2. Bestfit (GCG software) comparison of coding sequences of the cDNAs of PKS and pig uricase.

Figure 12-1 and 12-2. Bestfit (GCG software) comparison of coding sequences of the cDNAs of PKS and baboon uricase.

Figure 13-1 and 13-2. Bestfit (GCG software) comparison of coding sequences of the cDNAs of PBC and pig uricase.

Figure 14-1 and 14-2. Bestfit (GCG software) comparison of coding sequences of the cDNAs of PBC and baboon uricase.

Detailed Description of the Invention

The present invention provides uricase proteins which are useful intermediates for improved uricase conjugates of water-soluble polymers, preferably poly(ethylene glycols) or poly(ethylene oxides), with uricases. Uricase, as used herein, includes individual subunits as well as the native tetramer, unless otherwise indicated.

Although humans do not make an active enzyme, uricase mRNA transcripts have been amplified from human liver RNA (Wu et al. 1992). It is theoretically possible that some human uricase transcripts are translated; even if the peptide products were not full length or were unstable, they could be processed by antigen presenting cells and play a role in determining the immunlogic response to an exogenous uricase used for treatment. It may, in theory, be possible to reconstruct and express a human uricase cDNA by eliminating the two known nonsense mutations. However, in the absence of selective pressure, it is very likely that deleterious missense mutations have accumulated in the human gene during the millions of years since the first nonsense mutation was introduced (Wu et al. 1989; Wu et al. 1992). Identifying and "correcting" all mutations to obtain maximal catalytic activity and protein stability would be very difficult.

The present inventors have appreciated that there is a high degree of homology (similarity) between the deduced amino acid sequence of human uricase to those of pig (about 86%) and baboon (about 92%) (see, Figures 6-14, for example of measure of similarity), whereas homology (similarity) between human and *A. flavus* uricase is <40% (Lee et al. 1988; Reddy et al. 1988; Wu et al. 1989; Legoux et al. 1992; Wu et al. 1992). The present invention provides recombinantly produced chimeric uricase proteins from two different mammals which have been designed to be less immunoreactive to humans than more distantly related fungal or bacterial enzyme. Use of a mammalian uricase derivative is expected to be more acceptable to patients and their physicians.

Experience has shown that activated PEGs such as have been used to make PEG-ADA and to modify other proteins attach via primary amino groups of the amino terminal residue (when present and unblocked) and epsilon-amino groups of lysines. This strategy is useful both because mild reaction conditions can be used, and because positvely charged lysines tend to be located on the surfaces of proteins. The latter is important since for any therapeutic protein the desired effects of PEGylation will depend in part on the characteristics of the PEG polymer (e.g. mass, branched or unbranched stucture, etc.) as well as on the number and distribution of PEG attachment sites of the protein relative to the epitopes and structural elements that determine function and clearance of the protein. A strategy for enhancing the ability of PEGylation to 'mask' epitopes and reduce immunogenicity by semi-selectively introducing novel lysine residues for potential PEG addition has been devised (Hershfield et al. 1991). This strategy employs mutagenesis to replace selected arginine codons with lysine codons, a substitution that maintains positive charge and has minimal effect on computer-predicted indices of surface probability and antigenicity (useful when only amino acid sequence is known).

As an experimental test of this strategy, recombinant *E. coli* purine nucleoside phosphorylase (EPNP) (Hershfield et al. 1991) has been used. Arg-to-Lys substitutions at 3 sites were introduced, increasing the number of lysines per subunit from 14 to 17, without altering catalytic activity. The purified triple-mutant retained full activity after modification of ~70% of accessible NH_2 groups with excess disuccinyl-PEG5000.

Titration of reactive amino groups before and after PEGylation suggested that the triple mutant could accept one more PEG strand per subunit than the wild type enzyme. PEGylation increased the circulating life of both the wild type and mutant EPNP enzymes in mice from ~4 hours to >6 days. After a series of intraperitoneal injections at weekly/biweekly intervals, all mice treated with both unmodified EPNPs, and 10 of 16 mice (60%) injected with PEGylated wild type EPNP, developed high levels of anti-EPNP antibody and a marked decline in circulating life. In contrast, only 2/12 mice (17%) treated with the mutant PEG-EPNP developed rapid clearance; low levels of antibody in these mice did not correlate with circulating life. This strategy was thus successful in substantially reducing immunogenicity even though only 1 of the 3 new lysines became modified after treatment with activated PEG.

The baboon and pig uricase subunits each consist of 304 amino acids, 29 of which (i.e. 1 in about 10 residues) are lysines. Initially attempts to introduce 2 Arg-to-Lys substitutions into the cloned cDNA for baboon uricase, and also a substitution of Lys for a Glu codon at position 208, which is known to be a Lys in the human uricase gene, resulted in an expressed mutant baboon protein which had greatly reduced uricase catalytic activity. It was apparent from this experiment that the ability to maintain uricase enzyme activity after arginine to lysine mutation of the mammalian DNA sequence was not predictable.

Subsequently, it was appreciated that amino acid residue 291 in the baboon uricase is lysine, but the corresponding residue in pig is arginine. The ApaI restiction site present in both cDNAs was exploited to construct a chimeric uricase in which the first 225 amino acids are derived from the pig cDNA and the carboxy terminal 79 are derived from the baboon cDNA. The resulting pig-baboon chimeric (PBC) uricase (SEQ ID NO:2) possesses 30 lysines, one more than either "parental" enzyme. An additional feature of the PBC uricase is that its "baboon" portion differs from human uricase at 4 of 79 amino acid residues, whereas pig and human uricase differ at 10 in the same region. A modified version of PBC was subsequently constructed, which maintains the extra lysine at position 291 and otherwise differs from pig uricase only by a substituion of serine for threonine at residue 301 ("pigKS" uricase (SEQ ID NO:4)). In view of the results described in the preceding paragraph wherein several other insertions of lysines

were deleterious to activity, it was unexpected that the PBC and PKS chimeric uricase were fully as active as compared to the unmutated native pig uricase and approximately more than four fold active than unmutated native baboon uricase.

The present invention provides a recombinant pig-baboon chimeric uricase, composed of portions of the pig and baboon liver uricase sequences. One example of such a chimeric uricase contains the first 225 amino acids from the porcine uricase sequence (SEQ ID NO: 7) and the last 79 amino acids from the baboon uricase sequence (SEQ ID NO: 6) (pig-baboon uricase, or PBC uricase; Figure 6 and SEQ ID NO:2). Another example of such a chimeric uricase contains the first 288 amino acids from the porcine sequence (SEQ ID NO: 7) and the last 16 amino acids from the baboon sequence (SEQ ID NO: 6). Since the latter sequence differs from the porcine sequence at only two positions, having a lysine (K) in place of arginine at residue 291 and a serine (S) in place of threonine at residue 301, this mutant is referred to as pig-K-S or PKS uricase.

Vectors (expression and cloning) including the nucleic acid molecules coding the proteins of the present invention are also provided. Preferred vectors include those exemplified herein. One of ordinary skill will appreciate that nucleic acid molecules may be inserted into an expression vector, such as a plasmid, in proper orientation and correct reading frame for expression. If necessary, the nucleic acid (DNA) may be linked to appropriate transcriptional and translational regulatory nucleotide sequences recognized by the desired host, although such control elements are generally available in expression vectors used and known in the art. The vector may then be introduced into the host cells through standard techniques. Generally, not all of the host cells will be transformed by the vector. It may be necessary, therefore, to select transformed host cells. One such selection method known in the art involves incorporating into the expression vector a DNA sequence, with any necessary control elements, which codes for a selectable marker trait in the transformed cell, such as antibiotic resistance. Alternatively, the gene for such a selectable trait may be in another vector which is used to co-transform the desired host cells. The vectors can also include an appropriate promoter, such as a prokaryotic promoter capable of expression (transcripton and translation) of the DNA in a bacterial host cell, such as *E. coli*, transformed therewith.

Many expression systems are available and known in the art, including bacterial (for example *E. Coli* and *Bacillus subtilis*), yeasts (for example *Saccharomyces cerevisiae*), filamentous fungi (for example *Aspergillus*), plant cells, animal cells and insect cells.

Suitable vectors may include a prokaryotic replicon, such as ColE1 *ori*, for propagation in, for example, a prokaryote. Typical prokaryotic vector plasmids are pUC18, pUC19, pUC322 and pBR329 available from Biorad Laboratories (Richmond, CA) and pTcr99A and pKK223-3 available from Pharmacia (Piscataway, NJ). A typical mammalian cell vector plasmid is pSVL available from Pharmacia (Piscataway, NJ). This vector uses the SV40 late promoter to drive expression of cloned genes, the highest level of expression being found in T antigen-producing cells, such as COS-1 cells. An example of an inducible mammalian expression vector is pMSG, also available from Pharmacia. This vector uses the glucocorticoid-inducible promoter of the mouse mammary tumor virus long terminal repeat to drive expression of the cloned gene. Useful yeast plasmid vectors are pRS403-406 and pRS413-416, and are generally available from Stratagene Cloning Systems (LaJolla, CA). Plasmids pRS403, pRS404, pRS405, and pRS406 are Yeast Integrating plasmids (Yips) and incorporate the yeast selectable markers *HIS3, TRP1, LEU2 and URA3*. Plasmids pRS413-416 are Yeast Centomere plasmids (Ycps).

Moreover, the present invention provides host cells containing these vectors. Preferred host cells include those exemplified and described herein.

The uricase proteins of the present invention may be conjugated via a biologically stable, nontoxic, covalent linkage to a relatively small number of strands of PEG to improve the biological half-life and solubility of the proteins and reduce their immunoreactivity. Such linkages may include urethane (carbamate) linkages, secondary amine linkages, and amide linkages. Various activated PEGs suitable for such conjugation are commercially available from Shearwater Polymers, Huntsville, AL.

The invention also may be used to prepare pharmaceutical compositions of the uricase proteins as conjugates. These conjugates are substantially non-immunogenic and retain at least 70%, preferably 80%, and more preferably at least about 90% or more of the uricolytic activity of the unmodified enzyme. Water-soluble polymers suitable for use in the present invention include linear and branched poly(ethylene

glycols) or poly(ethylene oxides), all commonly known as PEGs. One example of branched PEG is the subject of U.S. Patent 5,643,575.

In one embodiment of the invention, the average number of lysines inserted per uricase subunit is between 1 and 10. In a preferred embodiment, the number of additional lysines per uricase subunit is between 2 and 8. It being understood that the number of additional lysines should not be so many as to be a detriment to the catalytic activity of the uricase. The PEG molecules of the conjugate are preferably conjugated through lysines of the uricase protein, more preferably, through a non-naturally occurring lysine or lysines which have been introduced into the portion of a designed protein which does not naturally contain a lysine at that position.

The present invention provides a method of increasing the available non-deleterious PEG attachment sites to a uricase protein wherein a native uricase protein is mutated in such a manner so as to introduce at least one lysine residue therein. Preferably, this method includes replacement of arginines with lysines.

PEG-uricase conjugates utilizing the present invention are useful for lowering the levels (i.e., reducing the amount) of uric acid in the blood and/or urine of mammals, preferably humans, and can thus be used for treatment of elevated uric acid levels associated with conditions including gout, tophi, renal insufficiency, organ transplantation and malignant disease.

PEG-uricase conjugates may be introduced into a mammal having excessive uric acid levels by any of a number of routes, including oral, by enema or suppository, intravenous, subcutaneous, intradermal, intramuscular and intraperitoneal routes. Patton, JS, et al., (1992) Adv Drug Delivery Rev 8:179-228.

The effective dose of PEG-uricase will depend on the level of uric acid and the size of the individual. In one embodiment of this aspect of the invention, PEG-uricase is administered in a pharmaceutically acceptable excipient or diluent in an amount ranging from 10 μg to about 1 g. In a preferred embodiment, the amount administered is between about 100 μg and 500 mg. More preferably, the conjugated uricase is administered in an amount between 1 mg and 100 mg, such as, for example, 5 mg, 20 mg, or 50 mg. Masses given for dosage amounts of the embodiments refer to the amount of protein in the conjugate.

Pharmaceutical formulations containing PEG-uricase can be prepared by conventional techniques, *e.g.*, as described in Remington's Pharmaceutical Sciences, (1985) Easton, PA: Mack Publishing Co. Suitable excipients for the preparation of injectable solutions include, for example, phosphate buffered saline, lactated Ringer's solution, water, polyols and glycerol. Pharmaceutical compositions for parenteral injection comprise pharmaceutically acceptable sterile aqueous or non-aqueous liquids, dispersions, suspensions, or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. These formulations can contain additional components, such as, for example, preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, buffers, antioxidants and diluents.

PEG-uricase may also be provided as controlled release compositions for implantation into an individual to continually control elevated uric acid levels in blood and urine. For example, polylactic acid, polyglycolic acid, regenerated collagen, poly-L-lysine, sodium alginate, gellan gum, chitosan, agarose, multilamellar liposomes and many other conventional depot formulations comprise bioerodible or biodegradable materials that can be formulated with biologically active compositions. These materials, when implanted or injected, gradually break down and release the active material to the surrounding tissue. For example, one method of encapsulating PEG-uricase comprises the method disclosed in U.S. Patent No. 5,653,974, which is hereby incorporated by reference. The use of bioerodible, biodegradable and other depot formulations is expressly contemplated in the present invention. The use of infusion pumps and matrix entrapment systems for delivery of PEG-uricase is also within the scope of the present invention. PEG-uricase may also advantageously be enclosed in micelles or liposomes. Liposome encapsulation technology is well known in the art. See, e.g., Lasic, D, et al., (Eds.) (1995) Stealth Liposomes, Boca Raton, FL: CRC Press.

The PEG-uricase pharmaceutical compositions described herein will decrease the need for hemodialysis in patients at high risk of urate-induced renal failure, *e.g.*, organ transplant recipients (see Venkataseshan, VS, et al., (1990) Nephron 56:317-321) and patients with some malignant diseases. In patients with large accumulations of crystalline urate (tophi), such pharmaceutical compositions will improve the quality of life more rapidly than currently available treatments.

The following examples, which are not to be construed as limiting the invention in any way, illustrate the various aspects disclosed above.

EXAMPLE 1

A. Construction of PBC, PKS and related uricase cDNAs.

Standard methods, and where applicable instructions supplied by the manufacturers of reagents, were used for preparing total cellular RNA, for PCR amplification (U.S. Patent Nos. 4,683,195 and 4,683,202, 4,965,188 & 5,075,216) of urate oxidase cDNAs, and for cloning and sequencing of these cDNAs (Erlich 1989; Sambrook et al. 1989; Ausubel 1998). PCR primers for pig and baboon urate oxidases (Table 1) were designed based on published coding sequences (Wu et al. 1989) and using the PRIME software program (Genetics Computer Group, Inc.).

Table 1. Primers for PCR Amplification of Urate Oxidase cDNA

Pig liver uricase cDNA:
sense: 5' gcgcgaattccATGGCTCATTACCGTAATGACTACA 3'.
Antisense: 5' gcgctctagaagcttccatggTCACAGCCTTGAAGTCAGC 3'.
D3H baboon liver uricase cDNA:
sense: 5' gcgcgaattccATGGCCCACTACCATAACAACTAT 3'
antisense: 5' gcgcccatggtctagaTCACAGTCTTGAAGACAACTTCCT

Restriction enzyme sequences (lowercase) introduced at the ends of the primers are sense (pig and baboon) EcoRI and NcoI; antisense (pig) NcoI, HindIII, XbaI; antisense (baboon) NcoI. In the case of baboon sense primer, the third codon GAC (Aspartate) present in baboon urate oxidase (Wu et al. 1992) was replaced with CAC (Histidine), the codon that is present at this position in the coding sequence of the human urate oxidase pseudogene (Wu et al. 1992). For this reason the recombinant

baboon urate oxidase generated from the use of these primers has been named D3H baboon urate oxidase.

Total cellular RNA from pig and baboon livers was reverse-transcribed using a 1st strand kit (Pharmacia Biotech Inc. Piscataway, NJ). PCR amplification using Taq DNA polymerase (GibcoBRL, Life Technologies, Gaithersburg, MD) was performed in a thermal cycler (Ericomp, San Diego, CA) with the program [30 s, 95°C; 30 s, 55°; 60 s, 70°], 20 cycles, followed by [30 s, 95°C; 60 s, 70°] 10 cycles. The urate oxidase PCR products were digested with EcoRI and HindIII and cloned into pUC18 (pig), and were also cloned directly (pig and D3H baboon) using the TA cloning system (Invitrogen, Carlsbad, CA). cDNA clones were transformed into the *E. coli* strain XL1-Blue (Stratagene, La Jolla, CA). Plasmid DNA containing cloned uricase cDNAs was prepared and the cDNA insert sequence was analyzed by standard dideoxy technique. Clones that possessed the published urate oxidase DNA coding sequences (except for the D3H substitution in baboon urate oxidase described in Table I) were constructed and verified in a series of subsequent steps by standard recombinant DNA methodology.

The pig and D3H baboon cDNAs containing full length coding sequences were introduced into pET expression vectors (Novagen, Madison, WI) as follows. The D3H baboon uricase cDNA was excised from the TA plasmid with the NcoI and BamHI restriction enzymes and then subcloned into the NcoI and BamHI cloning sites of the expression plasmids pET3d and pET9d. Full length pig uricase cDNA was excised from a pUC plasmid clone with the EcoRI and HindIII restriction enzymes and subcloned into the EcoRI and HindIII sites of pET28b. The pig cDNA coding region was also introduced into the NcoI and BlpI sites of the expression plasmid pET9d after excision from the NcoI and BlpI sites of pET28b.

The pig-baboon chimera (PBC) cDNA was constructed by excising the 624 bp NcoI-ApaI restriciton fragment of D3H baboon uricase cDNA from a pET3d-D3H-baboon clone, and then replacing this D3H baboon segment with the corresponding 624 bp NcoI-ApaI restriciton fragment of pig cDNA. The resulting PBC urate oxidase cDNA consists of the pig urate oxidase codons 1-225 joined in-frame to codons 226-304 of baboon urate oxidase.

The pig-KS urate oxidase (PigKS) cDNA was constructed by excising the 864 bp NcoI-NdeI restriciton fragment of D3H baboon uricase cDNA from a pET3d-D3H baboon clone, and then replacing this D3H baboon segment with the corresponding 864 bp NcoI-NdeI restriciton fragment of pig cDNA. The resulting PKS urate oxidase cDNA consists of the pig urate oxidase codons 1-288 joined in-frame to codons 289-304 of baboon urate oxidase.

The amino acid sequences of the D3H baboon, pig, PBC, and PKS urate oxidases are shown in Figure 5 and the SEQUENCE LISTING). Standard techniques were used to prepare 15% glycerol stocks of each of these transformants, and these were stored at -70°C. When each of these species was expressed and the recombinant enzymes isolated (Table 2), the pig, PBC chimera, and PigKS uricases had very similar specific activity, which was approximately 4-5 fold higher than the specific activity of recombinant baboon uricase. This order was confirmed in several other experiments. The specific activity of PBC uricase prepared by several different procedures varied over a 2-2.5-fold range.

Table 2:

Comparison of Expressed Recombinant Mammalian Uricases

Construct	Specific Activity* (Units/mg)	Relative Activity (Chimera=1)
PBC	7.02	1.00
PigKS	7.17	1.02
Pig	5.57	0.79
Baboon	1.36	0.19

* Protein was determined by the Lowry method. Uricase activity was determined spectrophotometrically (Priest and Pitts 1972). The assay was carried out at 23-25°C in a 1 cm quartz cuvette containing a 1 ml reaction mixture (0.1 M sodium borate, pH 8.6, 0.1 mM uric acid). Uric acid disappearance was monitored by decrease in absorbance at

292 nm. One international unit (IU) of uricase catalyzes the disappearance of one μmol of uric acid per minute.

E.coli BL21(DE3)pLysS transformants of the 4 uricase cDNA-pET constructs indicated in Table 2 were plated on LB agar containing selective antibiotics (carbenicillin and chloramphenicol for pET3d (pigKS); kanamycin and chloramphenicol for pET9d (PBC, pig, baboon)), as directed in the pET System Manual (Novagen, Madison WI). 5-ml cultures (LB plus antibiotics) were innoculated with single tranformant colonies and grown for 3 hours at 37°C. Then 0.1 ml aliquots were transferred to 100 ml of LB medium containing selective antibiotics and 0.1% lactose (to induce uricase expression). After overnight growth at 37°, bacterial cells from 0.5 ml aliquots of the cultures were extracted into SDS-PAGE loading buffer, and analyzed by SDS-mercaptoethanol PAGE; this established that comparable levels of uricase protein had been expressed in each of the 4 cultures (results not shown). The remaining cells from each 100 ml culture were harvested by centrifugation and washed in PBS. The cells were then re-suspended in 25 ml of phosphate-buffered saline, pH 7.4 (PBS) containing 1 mM AEBSF protease inhibitor (Calbiochem, San Diego, CA) and then lysed on ice in a Bacterial Cell Disruptor (Microfluidics, Boston MA). The insoluble material (including uricase) was pelleted by centrifugation (20,190 x g, 4°, 15 min). The pellets were washed twice with 10 ml of PBS, and then were extracted overnight at 4° with 2 ml of 1 M Na_2CO_3, pH 10.2. The extracts were diluted to 10 ml with water and then centrifuged (20,190 x g, 4°, 15 min). Uricase activity and protein concentrations were then determined.

EXAMPLE 2

Expression and isolation of recombinant PBC uricase (4 liter fermentor prep).

The pET3d-PBC uricase transformant was plated from a glycerol stock onto an LB agar plate containing carbenicillin and chloramphenicol, as directed in the Novagen pET System Manual. A 200 ml inoculum started from a single colony was prepared in

LB-antibiotic liquid medium on a rotary shaker (250 rpm) at 37°, using procedures recommended in the pET System Manual to maximize pET plasmid retention. At an OD_{525} of 2.4, cells from this 200 ml culture were collected by centrifugation and resuspended in 50 ml of fresh medium. This suspension was transferred to a high density fermentor containing 4 liters of carbenicillin- and chloramphenicol-containing SLBH medium (the composition of SLBH medium, and the design and operation of the fermentor are described in (Sadler et al. 1974)). After 20 hours of growth under O_2 at 32° (OD_{525} = 19) isopropylthiogalactoside (IPTG) was added to 0.4 mM to induce uricase production. After 6 more hours (OD_{525} = 37) bacterial cells were harvested by centrifugation (10,410 x g, 10 min, 4°C), washed once with PBS, and stored frozen at -20°C.

The bacterial cells (189 g) were resuspended in 200 ml PBS and lysed while cooled in an ice/salt bath by sonication (Heat Systems Sonicator XL, probe model CL, Farmingdale, NY) for 4 x 40 second bursts at 100% intensity, with a 1 minute rest between bursts. PBS-insoluble material (which includes uricase) was pelleted by centrifugation (10,410 x g, 10 min, 4°C), and was then washed 5 times with 200 ml PBS. Uricase in the PBS-insoluble pellet was extracted into 80 ml of 1 M Na_2CO_3, pH 10.2 containing 1 mM phenylmethylsulfonylfluoride (PMSF) and 130 µg/ml aprotinin. Insoluble debris was removed by centrifugation (20,190 x g, 2 hours, 4°C). All further steps in purification were at 4°C (results summarized in Table 3).

The pH 10.2 extract was diluted to 1800 ml with 1 mM PMSF (to reduce Na_2CO_3 to 0.075 M). This was applied to a column (2.6 x 9 cm) of fresh Q-Sepharose (Pharmacia Biotech, Inc., Piscataway, NJ), which had been equilbrated with 0.075 M Na_2CO_3, pH 10.2. After loading, the column was washed successively with 1) 0.075 M Na_2CO_3, pH 10.2 until A_{280} absorbance of the effluent reached background; 2) 10 mM $NaHCO_3$, pH 8.5 until the effluent pH fell to 8.5; 3) 50 ml of 10 mM $NaHCO_3$, pH 8.5, 0.15 M NaCl; 4) a 100-ml gradient of 0.15 M to 1.5 M NaCl in 10 mM $NaHCO_3$, pH 8.5; 5) 150 ml of 10 mM $NaHCO_3$ pH 8.5, 1.5 M NaCl; 6) 10 mM $NaHCO_3$ pH 8.5; 7) 0.1 M Na_2CO_3, pH 11 until the effluent pH was raised to 11. Finally, uricase was eluted with a 500 ml gradient from 0 to 0.6 M NaCl in 0.1 M Na_2CO_3, pH 11. The activity eluted in two A_{280}-absorbing peaks, which were pooled separately (Fraction A and

Fraction B, Table 3). Uricase in each of these pools was then precipitated by lowering the pH to 7.1 by slow addition of 1 M acetic acid, followed by centrifugation (7,000 x g, 10 min). The resulting pellets were dissolved in 50 ml of 1 M Na_2CO_3, pH 10.2 and stored at 4°C.

Table 3

Recombinant Pig-Baboon Chimeric (PBC) Uricase Purification

IPTG-induced Cell Paste = 189.6 g

Fraction	Total Protein mg	Uricase activity U/ml	Total Uricase Units	Specific Activity U/mg
pH 7 Sonicate + pH 7 Wash			74.9	
pH 10.2 Extract	4712	82.7	11,170	2.4
Q-Sepharose				
fraction A	820	11.5	1,081*	1.9
fraction B	1809	31.7	4,080	2.3
pH 7.1 precipitated & redissolved				
fraction A	598	35.0	1,748	3.0
fraction B	1586	75.5	3,773	2.4
Total Recovery	2184		5,521	

*The uricase present in fraction A began to precipitate spontaneously after elution from the column. Therefore activity measured at this stage of purification was underestimated.

EXAMPLE 3

Small scale preparation and PEGylation of recombinant PBC uricase.

This example shows that purified recombinant PBC uricase can be used to produce a PEGylated uricase. In this reaction, all uricase subunits were modified (Figure 1, lane 7), with retention of about 60% of catalytic activity (Table 4).

A. Small scale expression and isolation of PBC uricase (Table 4, Figure 1).

A 4-liter culture of *E.coli* BL21(DE3)pLysS transformed with pET3d-PBC cDNA was incubated on a rotary shaker (250 rpm) at 37°. At 0.7 OD_{525}, the culture was induced with IPTG (0.4 mM, 6 hours). The cells were harvested and frozen at -20°C. The cells (15.3 g) were disrupted by freezing and thawing, and extracted with 1 M Na_2CO_3, pH 10.2, 1 mM PMSF. After centrifugation (12,000 x g, 10 min, 4°C) the supernatant (85 ml) was diluted 1:10 with water and then chromatographed on Q-Sepharose in a manner similar to that described in Example 1. Pooled uricase activity from this step was concentrated by pressure ultrafiltration using a PM30 membrane (Amicon, Beverly, MA). The concentrate was chromatographed on a column (2.5 x 100 cm) of Sephacryl S-200 (Pharmacia Biotech, Piscataway, NJ) that was equilibrated and run in 0.1 M Na_2CO_3, pH 10.2. Fractions containing uricase activity were pooled and concentrated by pressure ultrafiltration, as above.

B. PEGylation.

100 mg of concentrated Sepahacryl S-200 PBC uricase (5 mg/ml, 2.9 µmol enzyme; 84.1 µmol lysine) in 0.1 M Na_2CO_3, pH 10.2 was allowed to react with a 2-fold excess (mol of PEG:mol uricase lysines) of an activated form of PEG at 4° for 60 min. The PEGylated uricase was freed from any unreacted or hydrolyzed PEG by tangential flow diafiltration. In this step the reaction was diluted 1:10 in 0.1 M Na_2CO_3, pH 10.2

and diafiltered vs. 3.5 vol 0.1 M Na_2CO_3, pH 10.2, then vs. 3.5 vol 0.05 M sodium phosphate, 0.15 M NaCl, pH 7.2. The filter-sterilized enzyme was stable at 4° for at least one month.

Table 4.

Summary of Purification and PEGylation of Recombinant Pig-Baboon Chimeric (PBC) Uricase

A. Purification Fraction	**Total protein**	**Total uricase activity**	**Specific activity**	**Recovery of activity**
	mg	*μmol/min*	*μmol/min/mg*	*%*
Crude extract	1565	1010	0.6	100
Q-Sepharose	355	1051	3.0	104
Sephacryl S-200	215	1170	5.5	116
B. PEGylation				
S-200 uricase	100	546	5.5	100
PEG-uricase	97	336	3.5	62

Figure 1 shows a SDS-mercaptoethanol PAGE (12% gel) analysis of fractions obtained during the purification and PEGylation of recombinant pig-baboon chimera (PBC) uricase. Lanes: 1= MW markers; 2= SDS extract of uninduced pET3d-PBC cDNA-transformed cells (*E. coli* BL21(DE3)pLysS); 3= SDS extract of IPTG-induced pET-PBC cDNA-transformed cells; 4= Crude extract (see Table 5); 5= concentrated Q-sepharose uricase pool; 6= concentrated Sephacryl S-200 uricase pool; 7= PEGylated Sephacryl S-200 recombinant PBC uricase.

The results shown in Table 4 show that the purified PBC uricase could be modified with retention of about 60% of catalytic activity. In this PEGylation reaction all of the uricase subunits were modified (Figure 1, lane 7). In studies not shown, the PEGylated enzyme had similar kinetic properties to unmodified PBC uricase (K_M 10-20

μM). Importantly, the modified enzyme was much more soluble than the unmodified enzyme at physiologic pH (>5 mg/ml in PBS vs. <1 mg/ml). The PEGylated enzyme could also be lyophilized and then reconstituted in PBS, pH 7.2, with minimal loss of activity. In other experiments, we compared the activities of this preparation of PEG-PBC uricase with the *A. flavus* uricase clinical preparation. At pH 8.6 in borate buffer, the *A. flavus* enzyme had 10-14 fold higher Vmax and a 2 fold higher K_M. However, in PBS, pH 7.2, the PEG-PBC and unmodified fungal enzymes differed in uricase activity by <2 fold.

EXAMPLE 4

Circulating life in mice of unmodified and PEGylated PBC uricase.

Figure 2 shows the circulating life of native and PEGylated PBC uricase. Groups of mice (3 per time point) were injected IP with 1 unit of native (circles) or PEG-modified (squares) recombinant PBC uricase (preparation described in Example 3). At the indicated times, blood was obtained from sets of three mice for measuring serum uricase activity. The PEGylated uricase (described in Example 3) had a circulating half-life of about 48 hours, vs. <2 hours for the unmodified enzyme (Fig 2).

EXAMPLE 5

Efficacy of PEGylated uricase of invention.

Figure 3 shows the relationship of serum uricase activity to the serum and urine concentrations of uric acid. In this experiment, a homozygous uricase-deficient knockout mouse (Wu et al. 1994) received two injections, at 0 and 72 hours, of 0.4 IU of recombinant PBC uricase that had been PEGylated. The uricase deficient knock-out mouse was used in this experiment because, unlike normal mice that have uricase, these knock-out mice, like humans, have high levels of uric acid in their blood and body

fluids and excrete high levels of uric acid in their urine. These high levels of uric acid cause serious injury to the kidneys of these mice, which is often fatal (Wu et al. 1994).

The experiment shown in Figure 3 demonstrates that intraperitoneal injections of a PEGylated preparation of recombinant PBC uricase resulted in an increase in serum uricase activity, which was accompanied by marked decline in the serum and urinary concentrations of uric acid in a uricase-deficient mouse.

EXAMPLE 6

Nonimmunogenicity of construct-carrier complex

PEGylated recombinant PBC uricase was injected repeatedly into homozygous uricase-deficient mice without inducing accelerated clearance, consistent with absence of significant immunogenicity. This was confirmed by ELISA. Figure 4 shows maintenance of circulating levels of uricase activity (measured in serum) after repeated injection. PEGylated PBC uricase was administered by intraperitoneal injection at 6-10 day intervals. Serum uricase activity was determined 24 hours post injection.

EXAMPLE 7

Covalent linkage to mutationally introduced lysine

PEGylation of purified recombinant PBC uricase should result in attachment of PEG to the novel lysine (residue 291). In this experiment a preparation of PBC uricase could be modified by PEGylation. It can be determined by means known in the art whether the peptide containing the novel lysine (residue 291) has been modified by PEGylation.

REFERENCES

Abuchowski A, Kazo GM, Verhoest CR, Jr., van Es T, Kafkewitz D, Nucci ML, Viau AT et al (1984) Cancer therapy with modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys 7:175-186

Abuchowski A, McCoy JR, Palczuk NC, van Es T, Davis FF (1977a) Effect of attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 252:3582-3586

Abuchowski A, van Es T, Palczuk NC, Davis FF (1977b) Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 252:3578-3581

Ausubel FM (1998) Current Protocols in Molecular Biology John Wiley & Sons

Ahn KJ, Kim YS, Lee HC, Park K, Huh KB (1992) Cyclosporine-induced hyperuricemia after renal transplant: Clinical characteristics and mechanisms. Transplantation Proceedings 24:1391-1392

Arellano F, Sacristan JA (1993) Allopurinol hypersensitivity syndrome: A review. Ann Pharmacother 27:337-343

Becker MA (1988) Clinical aspects of monosodium urate monohydrate crystal deposition disease (gout). Rheumatic Disease Clinics of North America 14:377-394

Becker MA, Roessler BJ (1995) Hyperuricemia and gout. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The Metabolic and Molecular Bases of Inherited Disease, 7 th ed. McGraw-Hill, New York, pp 1655-1677

Brogard JM, Coumaros D, Frankhauser J, Stahl A, Stahl J (1972) Enzymatic uricolysis: A study of the effect of a fungal urate-oxydase. Eur J Clin Biol Res 17:890-895

Brogard JM, Stahl A, Stahl J (1978) Enzymatic uricolysis and its use in therapy. In: Kelley WN, Arnold WJ, Weiner IM (eds) Uric Acid, Springer-Verlag, New York, pp515-524

Chaffee S, Mary A, Stiehm ER, Girault D, Fischer A, Hershfield MS (1992) IgG antibody response to polyethylene glycol-modified adenosine deaminase (PEG-ADA) in patients with adenosine deaminase deficiency. J Clin Invest 89:1643-1651

Chen RHL, Abuchowski A, van Es T, Palczuk NC, Davis FF (1981) Properties of two urate oxidases modified by the covalent attachment of poly(ethylene glycol). Biochim Biophys Acta 660:293-298

Chua CC, Greenberg ML, Viau AT, Nucci M, Brenckman WD, Jr., Hershfield MS (1988) Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma. Ann Int Med 109:114-117

Cohen LF, Balow JE, Magrath IT, Poplack DG, Ziegler JL (1980) Acute tumor lysis syndrome: A review of 37 patients with Burkitt's lymphoma. Am J Med 64:468-491

Conley TG, Priest DG (1979) Purification of uricase from mammalian tissue. Preparative Biochemistry 9:197-203

Davis FF, Kazo GM, Nucci ML, Abuchowski A (1991) Reduction of immunogenicity and extension of circulating life of peptides and proteins. In: Lee VHL (eds) Peptide and Protein Drug Delivery, Marcel Dekker, New York, pp831-864

Davis S, Abuchowski A, Park YK, Davis FF (1981a) Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol. Clin Exp Immunol 46:649-652

Davis S, Park YK, Abuchowski A, Davis FF (1981b) Hypouricaemic effect of polyethylene glycol modified urate oxidase. Lancet 1:281-283

Delaney V, Sumrani N, Daskalakis P, Hong JH, Sommer BG (1992) Hyperuricemia and gout in renal allograft recipients. Transplantation Proceedings 24:1773-1774

Donadio D, Errera J, Navarro M, Izarn P (1981) Anaphylaxis-like manifestations after intravenous injection of urate oxidase in an asthmatic child with acute leukemia (letter). Nouv Presse Med 10:711-712

Erlich HA (1989) PCR Technology. Principles and applications for DNA amplification Stockton Press, New York

Escudier B, Leclercq B, Tandonnet F, Nitenberg G (1984) Hyperuricemia resistant to urate oxidase. Efficacy of high doses (letter). Presse Med 13:1340

Fam AG (1990) Strategies and controversies in the treatment of gout and hyperuricaemia. Balliere's Clinical Rheumatology 4:177-192

George T, Mandell BF (1995) Gout in the transplant patient. J Clin Rheumatol 1:328-334

Gold GL, Fritz BD (1957) Hyperuricemia associated with the treatment of leukemia. Ann Int Med 47:428-434

Greenberg ML, Hershfield MS (1989) A radiochemical-high-performance liquid chromatographic assay for urate oxidase in human plasma. Anal Biochem 176:290-293

Harris JM, Zalipsky S (Ed.) (1997) Poly(ethylene glycol) Chemistry and Biological ApplicationsACS, Washington, DC

Hershfield M, S. (1997) Biochemistry and immunology of poly(ethylene glycol)-modified adenosine deaminase (PEG-ADA). In: Harris JM, Zalipsky S (eds) Poly(ethylene glycol) Chemistry and Biological Applications, ACS, Washington, DC, pp145-154

Hershfield MS (1995) PEG-ADA replacement therapy for adenosine deaminase deficiency: An update after 8.5 years. Clin Immunol Immunopathol 76:S228-S232

Hershfield MS (1996) Gout and uric acid metabolism. In: Bennett JC, Plum F (eds) Cecil Textbook of Medicine, XX ed. WB Saunders, New York, pp1508-1515

Hershfield MS, Buckley RH, Greenberg ML, Melton AL, Schiff R, Hatem C, Kurtzberg J et al (1987) Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med 316:589-596

Hershfield MS, Chaffee S, Koro-Johnson L, Mary A, Smith AA, Short SA (1991) Use of site-directed mutagenesis to enhance the epitope shielding effect of covalent modification of proteins with polyethylene glycol. Proc Natl Acad Sci USA 88:7185-7189

Hershfield MS, Mitchell BS (1995) Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The Metabolic and Molecular Bases of Inherited Disease, 7 th ed. McGraw-Hill, New York, pp1725-1768

Hershfield MS, Seegmiller JE (1976) Gout and the regulation of purine biosynthesis. In: Quagliariello E (eds) Horizons in Biochemistry and Biophysics, Addison-Wesley, Reading, MA, pp134-162

Jones DP, Stapleton FB, Kalwinsky D, McKay CP, Kellie SJ, Pui CH (1990) Renal dysfunction and hyperuricemia at presentation and relapse of acute lymphoblastic leukemia. Med Pediatr Oncol 18:283-286

Kelley WN, Fox IH, Pallela TD (1989) Gout and related disorders of purine metabolism. In: Kelley WN, Harris ED, Ruddy S, Sledge CG (eds) Textbook of Rheumatology, 3rd ed. WB Saunders, Philadelphia, pp1395-1448

Kissel P, Lamarche M, Royer R (1968) Modification of uricaemia and the excretion of uric acid nitrogen by an enzyme of fungal origin. Nature 217:72-74

Kissel P, Schmitt J, Streiff F, Makuary G, Schmidt C, Toussain P (1972) L'urate oxydase: son intérêt dans la prévention des hyperuricemies therapeutiques en hematologie. Ann Med Nancy 11:519-535

Lee CC, Wu X, Gibbs RA, Cook RG, Muzny DM, Caskey CT (1988) Generation of cDNA directed by amino acid sequence: Cloning of urate oxidase. Science 239:1288-1291

Legoux R, Delpech B, Dumont X, Guillemot JC, Ramond P, Shire D, Caput D et al (1992) Cloning and expression in *Escherichia coli* of the gene encoding *Aspergillus flavus* urate oxidase. J Biol Chem 267:8565-8570

London M, Hudson PM (1957) Uricolytic activity of purified uricase in two human beings. Science 125:937-938

Masera G, Jankovic M, Zurlo MG, Locasciulli A, Rossi MR, Uderzo C, Recchia M (1982) Urate-oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia. J Pediatr 100:152-155

Montagnac R, Schillinger F (1990) Anaphylactic complication tied to intravenous injection of urate oxidase. Nephrologie 11:259

Mourad G, Cristol JP, Chong G, Andary M, Mion C (1984) Role of precipitating anti-urate oxidase antibodies in urate oxidase-resistant hyperuricemia (letter). Presse Med 13:2585

Potaux L, Aparicio M, Maurel C, Ruedas ME, Martin-Dupont CL (1975) Uricolytic therapy. Value of urate oxidase in the treatment of hyperuricemias. Nouv Presse Med 4:1109-1112

Priest DG, Pitts OM (1972) Reaction intermediate effects on the spectrophotometric uricase assay. Analytical Biochemistry 50:195-205

Pui C-H, Relling MV, Lascombes F, Harrison PL, Struxiano A, Mondesir J-M, Riberio RC et al (1997) Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 11:1813-1816

Reddy PG, Nemali MR, Reddy MK, Reddy MN, Yuan PM, Yuen S, Laffler TG et al (1988) Isolation and sequence determination of a cDNA clone for rat peroxisomal urate oxidase: Liver-specific expression in the rat. Proc Natl Acad Sci USA 85:9081-9085

Rosenthal AK, Ryan LM (1995) Treatment of refractory crystal-associated arthtitis. Rheum Dis Clin North Amer 21:151-161

Roubenoff R (1990) Gout and hyperuricemia. Rheumatic Disease Clinics of North America 16:539-550

Sadler JR, Miwa J, Maas P, Smith T (1974) growth of high density bacterial cultures; a simple device. Laboratory Practice 23:632-643

Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning. A laboratory manual 2 nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, Pages

Sandberg AA, Cartwright GB, Wintrobe MM (1956) Studies on leukemia. I. Uric acid excretion. Blood 11:154-166

Savoca KV, Davis FF, Palczuk NC (1984) Induction of tolerance in mice by uricase and monomethoxypolyethylene glycol-modified uricase. Int Arch Allergy Appl Immunol 75:58-67

Sibony G, North ML, Bergerat JP, Lang JM, Oberling F (1984) Hyperuricemia resistant to urate oxidase. Role of anti-serum urate oxidase precipitating antibodies (letter). Presse Med 13:443

Singer JZ, Wallace SL (1986) The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum 29:82-87

Tsuji J, Hirose K, Kasahara E, Naitoh M, Yamamoto I (1985) Studies on the antigenicity of the polyethylene glycol-modified uricase. Int J Immunopharmacol 7:725-730

Venkataseshan VS, Feingold R, Dikman S, Churg J (1990) Acute hyperuricemic nephropathy and renal failure after transplantation. Nephron 56:317-321

Veronese FM, Caliceti P, Schiavon O (1997) New synthetic polymers for enzyme and liposome modification. In: Harris JM, Zalipsky S (eds) Poly(ethylene glycol) Chemistry and Biological Applications, ACS, Washington, DC, pp182-192

West C, Carpenter BJ, Hakala TR (1987) The incidence of gout in renal transplant recipients. Am J Kidney Dis 10:369-371

Wu X, Lee CC, Muzny DM, Caskey CT (1989) Urate oxidase: Primary structure and evolutionary implications. Proc Natl Acad Sci USA 86:9412-9416

Wu X, Muzny DM, Lee CC, Caskey CT (1992) Two independent mutational events in the loss of urate oxidase. J Mol Evol 34:78-84

Wu X, Wakamiya M, Vaishnav S, Geske R, Montgomery CM, Jr. , Jones P, Bradley A et al (1994) Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proc Natl Acad Sci USA 91:742-746

Zittoun R, Dauchy F, Teillaud C, Barthelemy M, Bouchard P (1976) Le traitement des hyperuricemies en hematologie par l'urate-oxydase et l'allopurinol. Ann Med Interne 127:479-482

* * * * * * *

All documents cited above are incorporated herein, in their entirety, by reference.

WE CLAIM:

1. A protein comprising a recombinant uricase protein of a mammalian species which has been modified to insert one or more lysine residues.

2. A protein according to claim 1 wherein said recombinant protein is a chimeric protein of two or more mammalian amino acid sequences.

3. A protein of claim 2 wherein said recombinant uricase chimeric protein comprises 304 amino acids, the first 225 N-terminal portion of said 304 amino acids being amino acids 1-225 of porcine uricase and the remaining 79 amino acids of said 304 amino acids being amino acids 226-304 of baboon uricase.

4. A protein of claim 2 wherein said recombinant uricase chimeric protein comprises 304 amino acids, the first 288 N-terminal portion of said 304 amino acids being amino acids 1-288 of porcine uricase and the remaining 16 amino acids of said 304 amino acids being amino acids 289-304 of baboon uricase.

5. A recombinant uricase protein selected from the group consisting of SEQ ID NO:s 2 , 4, 8, 9, 10 and 11.

6. An isolated and purified nucleic acid molecule coding the recombinant uricase of claim 1.

7. An isolated and purified nucleic acid molecule coding the recombinant uricase of claim 3.

8. An isolated and purified nucleic acid molecule coding a recombinant uricase of claim 4.

9. An isolated and purified nucleic acid molecule coding a recombinant uricase of claim 5.

10. An isolated and purified nucleic acid molecule of claim 9 having a base sequence of SEQ ID NO:1.

11. An isolated and purified nucleic acid molecule of claim 9 having a base sequence of SEQ ID NO:3.

12. A vector comprising a nucleic acid molecule of claim 1.

13. A vector comprising a nucleic acid molecule of claim 9.

14. A host cell comprising a vector according to claim 12.

15. A host cell comprising a vector according to claim 13.

16. A method of increasing the available non-deleterious PEG attachment sites to a uricase protein comprising mutating a uricase protein whereby at least one lysine residue is introduced therein.

17. A method of increasing the available non-deleterious PEG attachment sites to a uricase protein comprising mutating a uricase protein whereby at least one lysine residue is introduced therein in the place of an arginine.

Figure 1.




1
.1
.01
.001
Uricase activity, U/ml
PEG-modified
Native
0
1
2
3
4
5
6
Days after injection

Figure 2.


Serum Uric Acid, mg/dl
Urine Uric Acid, mg/dL
Serum Uricase Activity, U/ml
2nd injection of PEG-uricase
uricase activity
serum UAc
urine UAc
Hours after first injection of PEG-PBC Uricase

Figure 3.


10
1
0.1
0.01
Note: each point taken 24 h after an injection
Serum Uricase Activity, relative to initial activity
0
10
20
30
40
50
60
Days after first injection

Figure 4.

Figure 5

Deduced Amino Acid Sequences of Pig-Baboon Chimeric Uricase (PBC Uricase) and Porcine Uricase Containing the Mutations R291K and T301S (PKS Uricase). Compared with the Porcine and Baboon Sequences

Porcine	MAIYRNDYKK	NDEVEFVRTG	YGKDMIKVLH	IQRDGKYHSI	40
PBC	*1-225 porcine sequence →*				
PKS	*1-288 porcine sequence →*				
Baboon	MADYHNNYKK	NDELEFVRTG	YGKDMVKVLH	IQRDGKYHSI	40
Porcine	KEVATSVQLT	LSSKKDYLHG	DNSDVIPTDT	IKNTVNVLAK	80
PBC	*porcine sequence →*				
PKS	*porcine sequence →*				
Baboon	KEVATSVQLT	LSSKKDYLHG	DNSDIIPTDT	IKNTVHVLAK	80
Porcine	FKGIKSIETF	AVTICEHFLS	SFKHVIRAQV	YVEEVPWKRF	120
PBC	*porcine sequence →*				
PKS	*porcine sequence →*				
Baboon	FKGIKSIEAF	GVNICEYFLS	SFNHVIRAQV	YVEEIPWKRL	120
Porcine	EKNGVKHVHA	FIYTPTGTHF	CEVEQIRNGP	PVIHSGIKDL	160
PBC	*porcine sequence →*				
PKS	*porcine sequence →*				
Baboon	EKNGVKHVHA	FIHTPTGTHF	CEVEQLRSGP	PVIHSGIKDL	160
Porcine	KVLKTTQSGF	EGFIKDQFTT	LPEVKDRCFA	TQVYCKWRYH	200
PBC	*porcine sequence →*				
PKS	*porcine sequence →*				
Baboon	KVLKTTQSGF	EGFIKDQFTT	LPEVKDRCFA	TQVYCKWRYH	200
Porcine	QGRDVDFEAT	WDTVRSIVLQ	KFAGPYDKGE	YSPSVQKTLY	240
PBC	*porcine sequence*		→ | ← *baboon sequence*		
PKS	*porcine sequence →*				
Baboon	QCRDVDFEAT	WGTIRDLVLE	KFAGPYDKGE	YSPSVQKTLY	240
Porcine	DIQVLTLCQV	PEIEDMEISL	PNIHYLNIDM	SKMGLINKEE	280
PBC	*baboon sequence →*				
PKS	*porcine sequence →*				
Baboon	DIQVLSLSRV	PEIEDMEISL	PNIHYFNIDM	SKMGLINKEE	280

Porcine	VLLPLDNPYG	RITGTVKRKL	TSRL
PBC	*baboon sequence →*		*304*
PKS	*porcine* | ← *baboon*	*289-304*	
Baboon	VLLPLDNPYG	KITGTVKRKL	SSRL

Comparison of amino acid sequences "stripped-down" version of chimera, known as "PigKS" (also called "Pig-Lys") vs. Pig uricase

"Pig KS" uricase:
Pig cDNA from 1 to 864 (NdeI site) and then Baboon 865 to 915 (end)

Pig uricase:
Pig cDNA from 1 to 915 (end)

[GCG GAP program]
Gap Weight: 12 Average Match: 2.912
Length Weight: 4 Average Mismatch: -2.003

Quality: 1601 Length: 319
Ratio: 5.249 Gaps: 0
Percent Similarity: 99.672 Percent Identity: 99.344

Figure 6.

Match display thresholds for the alignment(s):
| = IDENTITY
: = 2
. = 1

pigKS.pep x Pig.pep June 25, 1998 17:11 ..

```
pigKS   1 MAHYRNDYKKNDEVEFVRTGYGKDMIKVLHIQRDGKYHSIKEVATSVQLT 50
          ||||||||||||||||||||||||||||||||||||||||||||||||||
Pig     1 MAHYRNDYKKNDEVEFVRTGYGKDMIKVLHIQRDGKYHSIKEVATSVQLT 50

         51 LSSKKDYLHGDNSDVIPTDTIKNTVNVLAKFKGIKSIETFAVTICEHFLS 100
            ||||||||||||||||||||||||||||||||||||||||||||||||||
         51 LSSKKDYLHGDNSDVIPTDTIKNTVNVLAKFKGIKSIETFAVTICEHFLS 100

        101 SFKHVIRAQVYVEEVPWKRFEKNGVKHVHAFIYTPTGTHFCEVEQIRNGP 150
            ||||||||||||||||||||||||||||||||||||||||||||||||||
        101 SFKHVIRAQVYVEEVPWKRFEKNGVKHVHAFIYTPTGTHFCEVEQIRNGP 150

        151 PVIHSGIKDLKVLKTTQSGFEGFIKDQFTTLPEVKDRCFATQVYCKWRYH 200
            ||||||||||||||||||||||||||||||||||||||||||||||||||
        151 PVIHSGIKDLKVLKTTQSGFEGFIKDQFTTLPEVKDRCFATQVYCKWRYH 200

        201 QGRDVDFEATWDTVRSIVLQKFAGPYDKGEYSPSVQKTLYDIQVLTLGQV 250
            ||||||||||||||||||||||||||||||||||||||||||||||||||
        201 QGRDVDFEATWDTVRSIVLQKFAGPYDKGEYSPSVQKTLYDIQVLTLGQV 250

        251 PEIEDMEISLPNIHYLNIDMSKMGLINKEEVLLPLDNPYGKITGTVKRKL 300
            ||||||||||||||||||||||||||||||||||||:||||||||||||
        251 PEIEDMEISLPNIHYLNIDMSKMGLINKEEVLLPLDNPYGRITGTVKRKL 300

        301 SSRL*  305
            .||||
        301 TSRL*. 305
```

Comparison of amino acid sequences of the "original" Pig-baboon chimeric uricase ("chimera") with that of the "stripped-down" version of chimera, known as "PigKS" (also called "Pig-Lys")

"Chimera" uricase:
Pig cDNA from 1 to 674 (Apa site) and then Baboon cDNA from 675 to 915 (end)

"Pig KS" uricase:
Pig cDNA from 1 to 864 (NdeI site) and then Baboon 865 to 915 (end)

[GCG GAP program]

Gap Weight:	12	Average Match:	2.912
Length Weight:	4	Average Mismatch:	-2.003
Quality:	1589	Length:	319
Ratio:	5.210	Gaps:	0
Percent Similarity:	98.689	Percent Identity:	98.689

Match display thresholds for the alignment(s):
| = IDENTITY
: = 2
. = 1

chimera.pep x pigKS.pep June 25, 1998 16:15

```
chim.   1 MAHYRNDYKKNDEVEFVRTGYGKDMIKVLHIQRDGKYHSIKEVATSVQLT 50
          ||||||||||||||||||||||||||||||||||||||||||||||||||
PigKS   1 MAHYRNDYKKNDEVEFVRTGYGKDMIKVLHIQRDGKYHSIKEVATSVQLT 50

         51 LSSKKDYLHGDNSDVIPTDTIKNTVNVLAKFKGIKSIETFAVTICEHFLS 100
            ||||||||||||||||||||||||||||||||||||||||||||||||||
         51 LSSKKDYLHGDNSDVIPTDTIKNTVNVLAKFKGIKSIETFAVTICEHFLS 100

        101 SFKHVIRAQVYVEEVPWKRFEKNGVKHVHAFIYTPTGTHFCEVEQIRNGP 150
            ||||||||||||||||||||||||||||||||||||||||||||||||||
        101 SFKHVIRAQVYVEEVPWKRFEKNGVKHVHAFIYTPTGTHFCEVEQIRNGP 150

        151 PVIHSGIKDLKVLKTTQSGFEGFIKDQFTTLPEVKDRCFATQVYCKWRYH 200
            ||||||||||||||||||||||||||||||||||||||||||||||||||
        151 PVIHSGIKDLKVLKTTQSGFEGFIKDQFTTLPEVKDRCFATQVYCKWRYH 200

        201 QGRDVDFEATWDTVRSIVLQKFAGPYDKGEYSPSVQKTLYDIQVLSLSRV 250
            |||||||||||||||||||||||||||||||||||||||||||| | | |
        201 QGRDVDFEATWDTVRSIVLQKFAGPYDKGEYSPSVQKTLYDIQVLTLGQV 250

        251 PEIEDMEISLPNIHYFNIDMSKMGLINKEEVLLPLDNPYGKITGTVKRKL 300
            |||||||||||||| ||||||||||||||||||||||||||||||||||||
        251 PEIEDMEISLPNIHYLNIDMSKMGLINKEEVLLPLDNPYGKITGTVKRKL 300

        301 SSRL*. 305
            |||||
        301 SSRL* 305
```

Comparison of amino acid sequences of the "original" Pig-baboon chimeric uricase ("chimera") with that of Pig uricase

"Chimera" uricase:
Pig cDNA from 1 to 674 (Apa site) and then Baboon cDNA from 675 to 915 (end)

Pig uricase:
Pig cDNA from 1 to 915 (end)

[GCG GAP program]
Gap Weight: 12 Average Match: 2.912
Length Weight: 4 Average Mismatch: -2.003

Quality: 1583 Length: 305
Ratio: 5.190 Gaps: 0
Percent Similarity: 98.361 Percent Identity: 98.033

Match display thresholds for the alignment(s):
| = IDENTITY
: = 2
. = 1

chimera.pep x Pig.pep June 25, 1998 16:54 ..

```
chim    1 MAHYRNDYKKNDEVEFVRTGYGKDMIKVLHIQRDGKYHSIKEVATSVQLT 50
          ||||||||||||||||||||||||||||||||||||||||||||||||||
Pig     1 MAHYRNDYKKNDEVEFVRTGYGKDMIKVLHIQRDGKYHSIKEVATSVQLT 50

       51 LSSKKDYLHGDNSDVIPTDTIKNTVNVLAKFKGIKSIETFAVTICEHFLS 100
          ||||||||||||||||||||||||||||||||||||||||||||||||||
       51 LSSKKDYLHGDNSDVIPTDTIKNTVNVLAKFKGIKSIETFAVTICEHFLS 100

      101 SFKHVIRAQVYVEEVPWKRFEKNGVKHVHAFIYTPTGTHFCEVEQIRNGP 150
          ||||||||||||||||||||||||||||||||||||||||||||||||||
      101 SFKHVIRAQVYVEEVPWKRFEKNGVKHVHAFIYTPTGTHFCEVEQIRNGP 150

      151 PVIHSGIKDLKVLKTTQSGFEGFIKDQFTTLPEVKDRCFATQVYCKWRYH 200
          ||||||||||||||||||||||||||||||||||||||||||||||||||
      151 PVIHSGIKDLKVLKTTQSGFEGFIKDQFTTLPEVKDRCFATQVYCKWRYH 200

      201 QGRDVDFEATWDTVRSIVLQKFAGPYDKGEYSPSVQKTLYDIQVLSLSRV 250
          ||||||||||||||||||||||||||||||||||||||||||||.| .|
      201 QGRDVDFEATWDTVRSIVLQKFAGPYDKGEYSPSVQKTLYDIQVLTLGQV 250

      251 PEIEDMEISLPNIHYFNIDMSKMGLINKEEVLLPLDNPYGKITGTVKRKL 300
          |||||||||||||| ||||||||||||||||||||||:|||||||||||
      251 PEIEDMEISLPNIHYLNIDMSKMGLINKEEVLLPLDNPYGRITGTVKRKL 300

      301 SSRL* 305
          .||||
      301 TSRL* 305
```

Comparison of amino acid sequence of the "original" Pig-baboon chimeric uricase ("chimera") with that of "Baboon D3H" uricase (Baboon except for His replacing Asp at amino acid 3)

Pig uricase:
Pig cDNA from 1 to 915 (end)

"Baboon D3H" uricase:
"Baboon D3H" cDNA from 1 to 915 (end)

[GCG GAP program]

Gap Weight:	12	Average Match:	2.912
Length Weight:	4	Average Mismatch:	-2.003
Quality:	1493	Length:	305
Ratio:	4.895	Gaps:	0
Percent Similarity:	94.098	Percent Identity:	90.820

Match display thresholds for the alignment(s):
| = IDENTITY
: = 2
. = 1

Pig.pep x baboon D3H.pep June 25, 1998 17:44 ..

```
Pig     1 MAHYRNDYKKNDEVEFVRTGYGKDMIKVLHIQRDGKYHSIKEVATSVQLT 50
          ||||  |.|||||.|||||||||||:|||||||||||||||||||||||
Bab     1 MAHYHNNYKKNDELEFVRTGYGKDMVKVLHIQRDGKYHSIKEVATSVQLT 50

       51 LSSKKDYLHGDNSDVIPTDTIKNTVNVLAKFKGIKSIETFAVTICEHFLS 100
          |||||||||||||||:||||||||||.|||||||||||| | | |||:|||
       51 LSSKKDYLHGDNSDIIPTDTIKNTVHVLAKFKGIKSIEAFGVNICEYFLS 100

      101 SFKHVIRAQVYVEEVPWKRFEKNGVKHVHAFIYTPTGTHFCEVEQIRNGP 150
          || ||||||||||||:|||| ||||||||||||:||||||||||||:|.||
      101 SFNHVIRAQVYVEEIPWKRLEKNGVKHVHAFIHTPTGTHFCEVEQLRSGP 150

      151 PVIHSGIKDLKVLKTTQSGFEGFIKDQFTTLPEVKDRCFATQVYCKWRYH 200
          ||||||||||||||||||||||||||||||||||||||||||||||||||
      151 PVIHSGIKDLKVLKTTQSGFEGFIKDQFTTLPEVKDRCFATQVYCKWRYH 200

      201 QGRDVDFEATWDTVRSIVLQKFAGPYDKGEYSPSVQKTLYDIQVLTLGQV 250
          | |||||||||| |:| :||:||||||||||||||||||||||||.| .|
      201 QCRDVDFEATWGTIRDLVLEKFAGPYDKGEYSPSVQKTLYDIQVLSLSRV 250

      251 PEIEDMEISLPNIHYLNIDMSKMGLINKEEVLLPLDNPYGRITGTVKRKL 300
          |||||||||||||||| ||||||||||||||||||||||:||||||||||
      251 PEIEDMEISLPNIHYFNIDMSKMGLINKEEVLLPLDNPYGKITGTVKRKL 300

      301 TSRL* 305
          .||||
      301 SSRL* 305
```

Figure 10.

Comparison of amino acid sequence of the "original" Pig-baboon chimeric uricase ("chimera") with that of "Baboon D3H" uricase (Baboon except for His replacing Asp at amino acid 3)

"Chimera" uricase:
Pig cDNA from 1 to 674 (Apa site) and then Baboon cDNA from 675 to 915 (end)

"Baboon D3H" uricase:
"Baboon D3H" cDNA from 1 to 915 (end)

[GCG GAP program]

Gap Weight:	12	Average Match:	2.912
Length Weight:	4	Average Mismatch:	-2.003
Quality:	1516	Length:	305
Ratio:	4.970	Gaps:	0
Percent Similarity:	95.738	Percent Identity:	92.787

Match display thresholds for the alignment(s):
| = IDENTITY
: = 2
. = 1

chimera.pep x baboon D3H.pep June 25, 1998 17:18

```
chim    1 MAHYRNDYKKNDEVEFVRTGYGKDMIKVLHIQRDGKYHSIKEVATSVQLT 50
          |||| |.|||||.|||||||||||:||||||||||||||||||||||||
Bab     1 MAHYHNNYKKNDELEFVRTGYGKDMVKVLHIQRDGKYHSIKEVATSVQLT 50

         51 LSSKKDYLHGDNSDVIPTDTIKNTVNVLAKFKGIKSIETFAVTICEHFLS 100
            |||||||||||||||:|||||||||||.|||||||||||| | | |||:|||
         51 LSSKKDYLHGDNSDIIPTDTIKNTVHVLAKFKGIKSIEAFGVNICEYFLS 100

        101 SFKHVIRAQVYVEEVPWKRFEKNGVKHVHAFIYTPTGTHFCEVEQIRNGP 150
            || |||||||||||:|||| ||||||||||||:||||||||||||:|.||
        101 SFNHVIRAQVYVEEIPWKRLEKNGVKHVHAFIHTPTGTHFCEVEQLRSGP 150

        151 PVIHSGIKDLKVLKTTQSGFEGFIKDQFTTLPEVKDRCFATQVYCKWRYH 200
            ||||||||||||||||||||||||||||||||||||||||||||||||||
        151 PVIHSGIKDLKVLKTTQSGFEGFIKDQFTTLPEVKDRCFATQVYCKWRYH 200

        201 QGRDVDFEATWDTVRSIVLQKFAGPYDKGEYSPSVQKTLYDIQVLSLSRV 250
            | |||||||||| |:| :||:||||||||||||||||||||||||||||
        201 QCRDVDFEATWGTIRDLVLEKFAGPYDKGEYSPSVQKTLYDIQVLSLSRV 250

        251 PEIEDMEISLPNIHYFNIDMSKMGLINKEEVLLPLDNPYGKITGTVKRKL 300
            ||||||||||||||||||||||||||||||||||||||||||||||||||
        251 PEIEDMEISLPNIHYFNIDMSKMGLINKEEVLLPLDNPYGKITGTVKRKL 300

        301 SSRL* 305
            |||||
        301 SSRL* 305
```

Figure 11-1

Bestfit (GCG software) comparison of coding sequences of the cDNAs of Pig KS uricase ("PKS") vs. pig uricase

"Pig KS" uricase:
Pig cDNA from 1 to 864 (NdeI site) and then Baboon 865 to 915 (end)

Gap Weight:	50	Average Match:	10.000
Length Weight:	3	Average Mismatch:	-9.000
Quality:	9036	Length:	915
Ratio:	9.875	Gaps:	0
Percent Similarity:	99.344	Percent Identity:	99.344

Match display thresholds for the alignment(s):
| = IDENTITY
: = 5
. = 1

pigKS.seq x pig.seq July 25, 1998 10:14 ..

```
PKS     1 ATGGCTCATTACCGTAATGACTACAAAAAGAATGATGAGGTAGAGTTTGT 50
          ||||||||||||||||||||||||||||||||||||||||||||||||||
pig     1 ATGGCTCATTACCGTAATGACTACAAAAAGAATGATGAGGTAGAGTTTGT 50

       51 CCGAACTGGCTATGGGAAGGATATGATAAAAGTTCTCCATATTCAGCGAG 100
          ||||||||||||||||||||||||||||||||||||||||||||||||||
       51 CCGAACTGGCTATGGGAAGGATATGATAAAAGTTCTCCATATTCAGCGAG 100

      101 ATGGAAAATATCACAGCATTAAAGAGGTGGCAACTTCAGTGCAACTGACT 150
          ||||||||||||||||||||||||||||||||||||||||||||||||||
      101 ATGGAAAATATCACAGCATTAAAGAGGTGGCAACTTCAGTGCAACTGACT 150

      151 TTGAGCTCCAAAAAAGATTACCTGCATGGAGACAATTCAGATGTCATCCC 200
          ||||||||||||||||||||||||||||||||||||||||||||||||||
      151 TTGAGCTCCAAAAAAGATTACCTGCATGGAGACAATTCAGATGTCATCCC 200

      201 TACAGACACCATCAAGAACACAGTTAATGTCCTGGCGAAGTTCAAAGGCA 250
          ||||||||||||||||||||||||||||||||||||||||||||||||||
      201 TACAGACACCATCAAGAACACAGTTAATGTCCTGGCGAAGTTCAAAGGCA 250

      251 TCAAAAGCATAGAAACTTTTGCTGTGACTATCTGTGAGCATTTCCTTTCT 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||
      251 TCAAAAGCATAGAAACTTTTGCTGTGACTATCTGTGAGCATTTCCTTTCT 300

      301 TCCTTCAAGCATGTCATCAGAGCTCAAGTCTATGTGGAAGAAGTTCCTTG 350
          ||||||||||||||||||||||||||||||||||||||||||||||||||
      301 TCCTTCAAGCATGTCATCAGAGCTCAAGTCTATGTGGAAGAAGTTCCTTG 350

      351 GAAGCGTTTTGAAAAGAATGGAGTTAAGCATGTCCATGCATTTATTTATA 400
          ||||||||||||||||||||||||||||||||||||||||||||||||||
      351 GAAGCGTTTTGAAAAGAATGGAGTTAAGCATGTCCATGCATTTATTTATA 400
```

Figure 11-2

```
401 CTCCTACTGGAACGCACTTCTGTGAGGTTGAACAGATAAGGAATGGACCT 450
    ||||||||||||||||||||||||||||||||||||||||||||||||||
401 CTCCTACTGGAACGCACTTCTGTGAGGTTGAACAGATAAGGAATGGACCT 450

451 CCAGTCATTCATTCTGGAATCAAAGACCTAAAAGTCTTGAAAACAACCCA 500
    ||||||||||||||||||||||||||||||||||||||||||||||||||
451 CCAGTCATTCATTCTGGAATCAAAGACCTAAAAGTCTTGAAAACAACCCA 500

501 GTCTGGCTTTGAAGGATTCATCAAGGACCAGTTCACCACCCTCCCTGAGG 550
    ||||||||||||||||||||||||||||||||||||||||||||||||||
501 GTCTGGCTTTGAAGGATTCATCAAGGACCAGTTCACCACCCTCCCTGAGG 550

551 TGAAGGACCGGTGCTTTGCCACCCAAGTGTACTGCAAATGGCGCTACCAC 600
    ||||||||||||||||||||||||||||||||||||||||||||||||||
551 TGAAGGACCGGTGCTTTGCCACCCAAGTGTACTGCAAATGGCGCTACCAC 600

601 CAGGGCAGAGATGTGGACTTTGAGGCCACCTGGGACACTGTTAGGAGCAT 650
    ||||||||||||||||||||||||||||||||||||||||||||||||||
601 CAGGGCAGAGATGTGGACTTTGAGGCCACCTGGGACACTGTTAGGAGCAT 650

651 TGTCCTGCAGAAATTTGCTGGGCCCTATGACAAAGGCGAGTACTCGCCCT 700
    ||||||||||||||||||||||||||||||||||||||||||||||||||
651 TGTCCTGCAGAAATTTGCTGGGCCCTATGACAAAGGCGAGTACTCGCCCT 700

701 CTGTCCAGAAGACACTCTATGACATCCAGGTGCTCACCCTGGGCCAGGTT 750
    ||||||||||||||||||||||||||||||||||||||||||||||||||
701 CTGTCCAGAAGACACTCTATGACATCCAGGTGCTCACCCTGGGCCAGGTT 750

751 CCTGAGATAGAAGATATGGAAATCAGCCTGCCAAATATTCACTACTTAAA 800
    ||||||||||||||||||||||||||||||||||||||||||||||||||
751 CCTGAGATAGAAGATATGGAAATCAGCCTGCCAAATATTCACTACTTAAA 800

801 CATAGACATGTCCAAAATGGGACTGATCAACAAGGAAGAGGTCTTGCTAC 850
    ||||||||||||||||||||||||||||||||||||||||||||||||||
801 CATAGACATGTCCAAAATGGGACTGATCAACAAGGAAGAGGTCTTGCTAC 850

851 CTTTAGACAATCCATATGGAAAAATTACTGGTACAGTCAAGAGGAAGTTG 900
    |||||||||||||||||| | ||||||||||||||||||||||| ||
851 CTTTAGACAATCCATATGGCAGGATTACTGGTACAGTCAAGAGGAAGCTG 900

901 TCTTCAAGACTGTGA 915
    |||||||  ||||||
901 ACTTCAAGGCTGTGA 915
```

Figure 12-1 13/18

Bestfit (GCG software) comparison of coding sequences of the cDNAs of Pig KS uricase ("PKS") vs. baboon uricase

"Pig KS" uricase:
Pig cDNA from 1 to 864 (NdeI site) and then Baboon 865 to 915 (end)

Gap Weight:	50	Average Match:	10.000
Length Weight:	3	Average Mismatch:	-9.000
Quality:	7573	Length:	915
Ratio:	8.277	Gaps:	0
Percent Similarity:	90.929	Percent Identity:	90.929

Match display thresholds for the alignment(s):
| = IDENTITY
: = 5
. = 1

pigKS.seq x baboon.seq July 25, 1998 10:21 ..

```
PKS     1 ATGGCTCATTACCGTAATGACTACAAAAAGAATGATGAGGTAGAGTTTGT 50
          |||||  | ||||  |||  ||||  ||||||||||||||  | |||||||||
bab     1 ATGGCCGACTACCATAACAACTATAAAAAGAATGATGAATTGGAGTTTGT 50

       51 CCGAACTGGCTATGGGAAGGATATGATAAAAGTTCTCCATATTCAGCGAG 100
          |||||||||||||||||||||||||| ||||||||||||||||||||||||
       51 CCGAACTGGCTATGGGAAGGATATGGTAAAAGTTCTCCATATTCAGCGAG 100

      101 ATGGAAAATATCACAGCATTAAAGAGGTGGCAACTTCAGTGCAACTGACT 150
          |||||||||||||||||||||||||||||||||||||||||||||||| |||
      101 ATGGAAAATATCACAGCATTAAAGAGGTGGCAACTTCAGTGCAACTTACT 150

      151 TTGAGCTCCAAAAAAGATTACCTGCATGGAGACAATTCAGATGTCATCCC 200
          ||||  |||||||||||||||||||||||||  |||||||||  ||||||||
      151 CTGAGTTCCAAAAAAGATTACCTGCATGGAGATAATTCAGATATCATCCC 200

      201 TACAGACACCATCAAGAACACAGTTAATGTCCTGGCGAAGTTCAAAGGCA 250
          |||||||||||||||||||||||||  |||||  ||||  |||||  ||  || |
      201 TACAGACACCATCAAGAACACAGTTCATGTCTTGGCAAAGTTTAAGGGAA 250

      251 TCAAAAGCATAGAAACTTTTGCTGTGACTATCTGTGAGCATTTCCTTTCT 300
          ||||||||||||||  | ||||  |||||  |||  ||||||  ||||  ||||||
      251 TCAAAAGCATAGAAGCCTTTGGTGTGAATATTTGTGAGTATTTTCTTTCT 300

      301 TCCTTCAAGCATGTCATCAGAGCTCAAGTCTATGTGGAAGAAGTTCCTTG 350
          ||  ||  ||  |||||  |||  ||||||||||||  |||||||||  | |||||
      301 TCTTTTAACCATGTAATCCGAGCTCAAGTCTACGTGGAAGAAATCCCTTG 350

      351 GAAGCGTTTTGAAAAGAATGGAGTTAAGCATGTCCATGCATTTATTTATA 400
          |||||||  |||||||||||||||||||||||||||||||||||||  | |
      351 GAAGCGTCTTGAAAAGAATGGAGTTAAGCATGTCCATGCATTTATTCACA 400
```

Figure 12-2.


401 CTCCTACTGGAACGCACTTCTGTGAGGTTGAACAGATAAGGAATGGACCT 450
401 CTCCCACTGGAACACACTTCTGTGAAGTTGAACAACTGAGAAGTGGACCC 450
451 CCAGTCATTCATTCTGGAATCAAAGACCTAAAAGTCTTGAAAACAACCCA 500
451 CCCGTCATTCATTCTGGAATCAAAGACCTCAAGGTCTTGAAAACAACACA 500
501 GTCTGGCTTTGAAGGATTCATCAAGGACCAGTTCACCACCCTCCCTGAGG 550
501 GTCTGGATTTGAAGGTTTCATCAAGGACCAGTTCACCACCCTCCCTGAGG 550
551 TGAAGGACCGGTGCTTTGCCACCCAAGTGTACTGCAAATGGCGCTACCAC 600
551 TGAAGGACCGATGCTTTGCCACCCAAGTGTACTGCAAGTGGCGCTACCAC 600
601 CAGGGCAGAGATGTGGACTTTGAGGCCACCTGGGACACTGTTAGGAGCAT 650
601 CAGTGCAGGGATGTGGACTTCGAGGCTACCTGGGGCACCATTCGGGACCT 650
651 TGTCCTGCAGAAATTTGCTGGGCCCTATGACAAAGGCGAGTACTCGCCCT 700
651 TGTCCTGGAGAAATTTGCTGGGCCCTATGACAAAGGCGAGTACTCACCCT 700
701 CTGTCCAGAAGACACTCTATGACATCCAGGTGCTCACCCTGGGCCAGGTT 750
701 CTGTGCAGAAGACCCTCTATGATATCCAGGTGCTCTCCCTGAGCCGAGTT 750
751 CCTGAGATAGAAGATATGGAAATCAGCCTGCCAAATATTCACTACTTAAA 800
751 CCTGAGATAGAAGATATGGAAATCAGCCTGCCAAACATTCACTACTTCAA 800
801 CATAGACATGTCCAAAATGGGACTGATCAACAAGGAAGAGGTCTTGCTAC 850
801 TATAGACATGTCCAAAATGGGTCTGATCAACAAGGAAGAGGTCTTGCTGC 850
851 CTTTAGACAATCCATATGGAAAAATTACTGGTACAGTCAAGAGGAAGTTG 900
851 CATTAGACAATCCATATGGAAAAATTACTGGTACAGTCAAGAGGAAGTTG 900
901 TCTTCAAGACTGTGA 915
901 TCTTCAAGACTGTGA 915

Figure 13-1.

Bestfit (GCG software) comparison of coding sequences of the cDNAs of "original" pig-baboon chimeric uricase ("PBC") vs. pig uricase

"PBC" uricase:
Pig cDNA from 1 to 674 (Apa site) then Baboon cDNA from 675 to 915 (end). PBC chimeric cDNA can be cut out with NcoI plus BamHI

```
      Gap Weight:     50      Average Match: 10.000
   Length Weight:      3   Average Mismatch: -9.000

         Quality:   8770             Length:    915
           Ratio:  9.585              Gaps:      0
Percent Similarity: 97.814   Percent Identity: 97.814

   Match display thresholds for the alignment(s):
                | = IDENTITY
                : =   5
                . =   1

PBC.seq x pig.seq        July 25, 1998 08:10

PBC     1 ATGGCTCATTACCGTAATGACTACAAAAAGAATGATGAGGTAGAGTTTGT 50
          ||||||||||||||||||||||||||||||||||||||||||||||||||
PIG     1 ATGGCTCATTACCGTAATGACTACAAAAAGAATGATGAGGTAGAGTTTGT 50

       51 CCGAACTGGCTATGGGAAGGATATGATAAAAGTTCTCCATATTCAGCGAG 100
          ||||||||||||||||||||||||||||||||||||||||||||||||||
       51 CCGAACTGGCTATGGGAAGGATATGATAAAAGTTCTCCATATTCAGCGAG 100

      101 ATGGAAAATATCACAGCATTAAAGAGGTGGCAACTTCAGTGCAACTGACT 150
          ||||||||||||||||||||||||||||||||||||||||||||||||||
      101 ATGGAAAATATCACAGCATTAAAGAGGTGGCAACTTCAGTGCAACTGACT 150

      151 TTGAGCTCCAAAAAAGATTACCTGCATGGAGACAATTCAGATGTCATCCC 200
          ||||||||||||||||||||||||||||||||||||||||||||||||||
      151 TTGAGCTCCAAAAAAGATTACCTGCATGGAGACAATTCAGATGTCATCCC 200

      201 TACAGACACCATCAAGAACACAGTTAATGTCCTGGCGAAGTTCAAAGGCA 250
          ||||||||||||||||||||||||||||||||||||||||||||||||||
      201 TACAGACACCATCAAGAACACAGTTAATGTCCTGGCGAAGTTCAAAGGCA 250

      251 TCAAAAGCATAGAAACTTTTGCTGTGACTATCTGTGAGCATTTCCTTTCT 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||
      251 TCAAAAGCATAGAAACTTTTGCTGTGACTATCTGTGAGCATTTCCTTTCT 300

      301 TCCTTCAAGCATGTCATCAGAGCTCAAGTCTATGTGGAAGAAGTTCCTTG 350
          ||||||||||||||||||||||||||||||||||||||||||||||||||
      301 TCCTTCAAGCATGTCATCAGAGCTCAAGTCTATGTGGAAGAAGTTCCTTG 350

      351 GAAGCGTTTTGAAAAGAATGGAGTTAAGCATGTCCATGCATTTATTTATA 400
          ||||||||||||||||||||||||||||||||||||||||||||||||||
      351 GAAGCGTTTTGAAAAGAATGGAGTTAAGCATGTCCATGCATTTATTTATA 400
```

Figure 13-2.

```
401 CTCCTACTGGAACGCACTTCTGTGAGGTTGAACAGATAAGGAATGGACCT 450
    ||||||||||||||||||||||||||||||||||||||||||||||||||
401 CTCCTACTGGAACGCACTTCTGTGAGGTTGAACAGATAAGGAATGGACCT 450

451 CCAGTCATTCATTCTGGAATCAAAGACCTAAAAGTCTTGAAAACAACCCA 500
    ||||||||||||||||||||||||||||||||||||||||||||||||||
451 CCAGTCATTCATTCTGGAATCAAAGACCTAAAAGTCTTGAAAACAACCCA 500

501 GTCTGGCTTTGAAGGATTCATCAAGGACCAGTTCACCACCCTCCCTGAGG 550
    ||||||||||||||||||||||||||||||||||||||||||||||||||
501 GTCTGGCTTTGAAGGATTCATCAAGGACCAGTTCACCACCCTCCCTGAGG 550

551 TGAAGGACCGGTGCTTTGCCACCCAAGTGTACTGCAAATGGCGCTACCAC 600
    ||||||||||||||||||||||||||||||||||||||||||||||||||
551 TGAAGGACCGGTGCTTTGCCACCCAAGTGTACTGCAAATGGCGCTACCAC. 600

601 CAGGGCAGAGATGTGGACTTTGAGGCCACCTGGGACACTGTTAGGAGCAT 650
    ||||||||||||||||||||||||||||||||||||||||||||||||||
601 CAGGGCAGAGATGTGGACTTTGAGGCCACCTGGGACACTGTTAGGAGCAT 650

651 TGTCCTGCAGAAATTTGCTGGGCCCTATGACAAAGGCGAGTACTCACCCT 700
    ||||||||||||||||||||||||||||||||||||||||||||| ||||
651 TGTCCTGCAGAAATTTGCTGGGCCCTATGACAAAGGCGAGTACTCGCCCT 700

701 CTGTGCAGAAGACCCTCTATGATATCCAGGTGCTCTCCCTGAGCCGAGTT 750
    |||| |||||||| |||||||| |||||||||||| ||||| ||| |||
701 CTGTCCAGAAGACACTCTATGACATCCAGGTGCTCACCCTGGGCCAGGTT 750

751 CCTGAGATAGAAGATATGGAAATCAGCCTGCCAAACATTCACTACTTCAA 800
    |||||||||||||||||||||||||||||||||||| |||||||||||||
751 CCTGAGATAGAAGATATGGAAATCAGCCTGCCAAATATTCACTACTTAAA 800

801 TATAGACATGTCCAAAATGGGTCTGATCAACAAGGAAGAGGTCTTGCTGC 850
    |||||||||||||||||||| |||||||||||||||||||||||||||||
801 CATAGACATGTCCAAAATGGGACTGATCAACAAGGAAGAGGTCTTGCTAC 850

851 CATTAGACAATCCATATGGAAAAATTACTGGTACAGTCAAGAGGAAGTTG 900
    | |||||||||||||||||| | ||||||||||||||||||||||||||
851 CTTTAGACAATCCATATGGCAGGATTACTGGTACAGTCAAGAGGAAGCTG 900

901 TCTTCAAGACTGTGA 915
    ||||||| ||||||
901 ACTTCAAGGCTGTGA 915
```

Bestfit (GCG software) comparison of coding sequences of the cDNAs of "original" pig-baboon chimeric uricase ("PBC") vs. baboon uricase

"PBC" uricase:
Pig cDNA from 1 to 674 (Apa site) then Baboon cDNA from 675 to 915 (end). PBC chimeric cDNA can be cut out with NcoI plus BamHI

Gap Weight:	50	Average Match:	10.000
Length Weight:	3	Average Mismatch:	-9.000
Quality:	7839	Length:	915
Ratio:	8.567	Gaps:	0
Percent Similarity:	92.459	Percent Identity:	92.459

Match display thresholds for the alignment(s):
| = IDENTITY
: = 5
. = 1

PBC.seq x Wubaboon.seq July 25, 1998 09:36

```
PBC     1 ATGGCTCATTACCGTAATGACTACAAAAAGAATGATGAGGTAGAGTTTGT 50
          |||||   | ||||  |||  ||||  ||||||||||||||   | |||||||||
Bab     1 ATGGCCGACTACCATAACAACTATAAAAAGAATGATGAATTGGAGTTTGT 50

       51 CCGAACTGGCTATGGGAAGGATATGATAAAAGTTCTCCATATTCAGCGAG 100
          |||||||||||||||||||||||||| ||||||||||||||||||||||||
       51 CCGAACTGGCTATGGGAAGGATATGGTAAAAGTTCTCCATATTCAGCGAG 100

      101 ATGGAAAATATCACAGCATTAAAGAGGTGGCAACTTCAGTGCAACTGACT 150
          |||||||||||||||||||||||||||||||||||||||||||||||| |||
      101 ATGGAAAATATCACAGCATTAAAGAGGTGGCAACTTCAGTGCAACTTACT 150

      151 TTGAGCTCCAAAAAAGATTACCTGCATGGAGACAATTCAGATGTCATCCC 200
          ||||  |||||||||||||||||||||||||| |||||||||  |||||||
      151 CTGAGTTCCAAAAAAGATTACCTGCATGGAGATAATTCAGATATCATCCC 200

      201 TACAGACACCATCAAGAACACAGTTAATGTCCTGGCGAAGTTCAAAGGCA 250
          |||||||||||||||||||||||| ||||| |||| |||||  ||  ||  |
      201 TACAGACACCATCAAGAACACAGTTCATGTCTTGGCAAAGTTTAAGGGAA 250

      251 TCAAAAGCATAGAAACTTTTGCTGTGACTATCTGTGAGCATTTCCTTTCT 300
          ||||||||||||||  | |||| ||||| ||| |||||| |||| ||||||
     -251 TCAAAAGCATAGAAGCCTTTGGTGTGAATATTTGTGAGTATTTTCTTTCT 300

      301 TCCTTCAAGCATGTCATCAGAGCTCAAGTCTATGTGGAAGAAGTTCCTTG 350
          ||  ||  ||  |||||  |||  |||||||||||| |||||||||  | |||||
      301 TCTTTTAACCATGTAATCCGAGCTCAAGTCTACGTGGAAGAAATCCCTTG 350

      351 GAAGCGTTTTGAAAAGAATGGAGTTAAGCATGTCCATGCATTTATTTATA 400
          |||||||  |||||||||||||||||||||||||||||||||||||| | |
      351 GAAGCGTCTTGAAAAGAATGGAGTTAAGCATGTCCATGCATTTATTCACA 400
```

```
401 CTCCTACTGGAACGCACTTCTGTGAGGTTGAACAGATAAGGAATGGACCT 450
    |||| |||||||| |||||||||| |||||||| | || | ||||||
401 CTCCCACTGGAACACACTTCTGTGAAGTTGAACAACTGAGAAGTGGACCC 450

451 CCAGTCATTCATTCTGGAATCAAAGACCTAAAAGTCTTGAAAACAACCCA 500
    || ||||||||||||||||||||||||||| || |||||||||||||| ||
451 CCCGTCATTCATTCTGGAATCAAAGACCTCAAGGTCTTGAAAACAACACA 500

501 GTCTGGCTTTGAAGGATTCATCAAGGACCAGTTCACCACCCTCCCTGAGG 550
    |||||| |||||||| ||||||||||||||||||||||||||||||||
501 GTCTGGATTTGAAGGTTTCATCAAGGACCAGTTCACCACCCTCCCTGAGG 550

551 TGAAGGACCGGTGCTTTGCCACCCAAGTGTACTGCAAATGGCGCTACCAC 600
    |||||||||| |||||||||||||||||||||||| ||||||||||||
551 TGAAGGACCGATGCTTTGCCACCCAAGTGTACTGCAAGTGGCGCTACCAC 600

601 CAGGGCAGAGATGTGGACTTTGAGGCCACCTGGGACACTGTTAGGAGCAT 650
    ||| |||| |||||||||||| ||||| ||||||| ||| || || | |
601 CAGTGCAGGGATGTGGACTTCGAGGCTACCTGGGGCACCATTCGGGACCT 650

651 TGTCCTGCAGAAATTTGCTGGGCCCTATGACAAAGGCGAGTACTCACCCT 700
    ||||||| |||||||||||||||||||||||||||||||||||||||||
651 TGTCCTGGAGAAATTTGCTGGGCCCTATGACAAAGGCGAGTACTCACCCT 700

701 CTGTGCAGAAGACCCTCTATGATATCCAGGTGCTCTCCCTGAGCCGAGTT 750
    |||||||||||||||||||||||||||||||||||||||||||||||||
701 CTGTGCAGAAGACCCTCTATGATATCCAGGTGCTCTCCCTGAGCCGAGTT 750

751 CCTGAGATAGAAGATATGGAAATCAGCCTGCCAAACATTCACTACTTCAA 800
    |||||||||||||||||||||||||||||||||||||||||||||||||
751 CCTGAGATAGAAGATATGGAAATCAGCCTGCCAAACATTCACTACTTCAA 800

801 TATAGACATGTCCAAAATGGGTCTGATCAACAAGGAAGAGGTCTTGCTGC 850
    |||||||||||||||||||||||||||||||||||||||||||||||||
801 TATAGACATGTCCAAAATGGGTCTGATCAACAAGGAAGAGGTCTTGCTGC 850

851 CATTAGACAATCCATATGGAAAAATTACTGGTACAGTCAAGAGGAAGTTG 900
    |||||||||||||||||||||||||||||||||||||||||||||||||
851 CATTAGACAATCCATATGGAAAAATTACTGGTACAGTCAAGAGGAAGTTG 900

901 TCTTCAAGACTGTGA 915
    ||||||||||||||
901 TCTTCAAGACTGTGA 915
```

SEQUENCE LISTING

<110> HERSHFIELD, MICHAEL S.
KELLY, SUSAN J.

<120> URATE OXIDASE

<130> 1579-267

<140>
<141>

<160>11

<170> PatentIn Ver. 2.0

<210> 1
<211> 915
<212> DNA
<213> Artificial Sequence

<220>
<221> CDS
<222> (1)..(915)

<220>
<223> Description of Artificial Sequence:PBC CHIMERA

<400> 1

```
atg gct cat tac cgt aat gac tac aaa aag aat gat gag gta gag ttt   48
Met Ala His Tyr Arg Asn Asp Tyr Lys Lys Asn Asp Glu Val Glu Phe
  1               5                  10                  15

gtc cga act ggc tat ggg aag gat atg ata aaa gtt ctc cat att cag   96
Val Arg Thr Gly Tyr Gly Lys Asp Met Ile Lys Val Leu His Ile Gln
            20                  25                  30

cga gat gga aaa tat cac agc att aaa gag gtg gca act tca gtg caa   144
Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln
        35                  40                  45

ctg act ttg agc tcc aaa aaa gat tac ctg cat gga gac aat tca gat   192
Leu Thr Leu Ser Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp
    50                  55                  60

gtc atc cct aca gac acc atc aag aac aca gtt aat gtc ctg gcg aag   240
Val Ile Pro Thr Asp Thr Ile Lys Asn Thr Val Asn Val Leu Ala Lys
65                  70                  75                  80

ttc aaa ggc atc aaa agc ata gaa act ttt gct gtg act atc tgt gag   288
Phe Lys Gly Ile Lys Ser Ile Glu Thr Phe Ala Val Thr Ile Cys Glu
                85                  90                  95

cat ttc ctt tct tcc ttc aag cat gtc atc aga gct caa gtc tat gtg   336
His Phe Leu Ser Ser Phe Lys His Val Ile Arg Ala Gln Val Tyr Val
            100                 105                 110

gaa gaa gtt cct tgg aag cgt ttt gaa aag aat gga gtt aag cat gtc   384
Glu Glu Val Pro Trp Lys Arg Phe Glu Lys Asn Gly Val Lys His Val
        115                 120                 125

cat gca ttt att tat act cct act gga acg cac ttc tgt gag gtt gaa   432
His Ala Phe Ile Tyr Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu
```

```
   130                 135                 140

cag ata agg aat gga cct cca gtc att cat tct gga atc aaa gac cta   480
Gln Ile Arg Asn Gly Pro Pro Val Ile His Ser Gly Ile Lys Asp Leu
145                 150                 155                 160

aaa gtc ttg aaa aca acc cag tct ggc ttt gaa gga ttc atc aag gac   528
Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp
                165                 170                 175

cag ttc acc acc ctc cct gag gtg aag gac cgg tgc ttt gcc acc caa   576
Gln Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Gln
            180                 185                 190

gtg tac tgc aaa tgg cgc tac cac cag ggc aga gat gtg gac ttt gag   624
Val Tyr Cys Lys Trp Arg Tyr His Gln Gly Arg Asp Val Asp Phe Glu
        195                 200                 205

gcc acc tgg gac act gtt agg agc att gtc ctg cag aaa ttt gct ggg   672
Ala Thr Trp Asp Thr Val Arg Ser Ile Val Leu Gln Lys Phe Ala Gly
    210                 215                 220

ccc tat gac aaa ggc gag tac tca ccc tct gtg cag aag acc ctc tat   720
Pro Tyr Asp Lys Gly Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr
225                 230                 235                 240

gat atc cag gtg ctc tcc ctg agc cga gtt cct gag ata gaa gat atg   768
Asp Ile Gln Val Leu Ser Leu Ser Arg Val Pro Glu Ile Glu Asp Met
                245                 250                 255

gaa atc agc ctg cca aac att cac tac ttc aat ata gac atg tcc aaa   816
Glu Ile Ser Leu Pro Asn Ile His Tyr Phe Asn Ile Asp Met Ser Lys
            260                 265                 270

atg ggt ctg atc aac aag gaa gag gtc ttg ctg cca tta gac aat cca   864
Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro
        275                 280                 285

tat gga aaa att act ggt aca gtc aag agg aag ttg tct tca aga ctg   912
Tyr Gly Lys Ile Thr Gly Thr Val Lys Arg Lys Leu Ser Ser Arg Leu
    290                 295                 300

tga                                                               915

305
```

<210> 2
<211> 304
<212> PRT
<213> Artificial Sequence

<400> 2

```
Met Ala His Tyr Arg Asn Asp Tyr Lys Lys Asn Asp Glu Val Glu Phe
  1               5                  10                  15

Val Arg Thr Gly Tyr Gly Lys Asp Met Ile Lys Val Leu His Ile Gln
            20                  25                  30

Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln
        35                  40                  45

Leu Thr Leu Ser Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp
```

50 55 60

Val Ile Pro Thr Asp Thr Ile Lys Asn Thr Val Asn Val Leu Ala Lys
65 70 75 80

Phe Lys Gly Ile Lys Ser Ile Glu Thr Phe Ala Val Thr Ile Cys Glu
85 90 95

His Phe Leu Ser Ser Phe Lys His Val Ile Arg Ala Gln Val Tyr Val
100 105 110

Glu Glu Val Pro Trp Lys Arg Phe Glu Lys Asn Gly Val Lys His Val
115 120 125

His Ala Phe Ile Tyr Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu
130 135 140

Gln Ile Arg Asn Gly Pro Pro Val Ile His Ser Gly Ile Lys Asp Leu
145 150 155 160

Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp
165 170 175

Gln Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Gln
180 185 190

Val Tyr Cys Lys Trp Arg Tyr His Gln Gly Arg Asp Val Asp Phe Glu
195 200 205

Ala Thr Trp Asp Thr Val Arg Ser Ile Val Leu Gln Lys Phe Ala Gly
210 215 220

Pro Tyr Asp Lys Gly Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr
225 230 235 240

Asp Ile Gln Val Leu Ser Leu Ser Arg Val Pro Glu Ile Glu Asp Met
245 250 255

Glu Ile Ser Leu Pro Asn Ile His Tyr Phe Asn Ile Asp Met Ser Lys
260 265 270

Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro
275 280 285

Tyr Gly Lys Ile Thr Gly Thr Val Lys Arg Lys Leu Ser Ser Arg Leu
290 295 300

<210> 3
<211> 915
<212> DNA
<213> Artificial Sequence

<220>
<221> CDS
<222> (1)..(915)

<220>
<223> Description of Artificial Sequence:pks chimera

<400> 3
atg gct cat tac cgt aat gac tac aaa aag aat gat gag gta gag ttt 48
Met Ala His Tyr Arg Asn Asp Tyr Lys Lys Asn Asp Glu Val Glu Phe

```
1               5                  10                  15

gtc cga act ggc tat ggg aag gat atg ata aaa gtt ctc cat att cag   96
Val Arg Thr Gly Tyr Gly Lys Asp Met Ile Lys Val Leu His Ile Gln
            20                  25                  30

cga gat gga aaa tat cac agc att aaa gag gtg gca act tca gtg caa   144
Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln
        35                  40                  45

ctg act ttg agc tcc aaa aaa gat tac ctg cat gga gac aat tca gat   192
Leu Thr Leu Ser Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp
    50                  55                  60

gtc atc cct aca gac acc atc aag aac aca gtt aat gtc ctg gcg aag   240
Val Ile Pro Thr Asp Thr Ile Lys Asn Thr Val Asn Val Leu Ala Lys
65                  70                  75                  80

ttc aaa ggc atc aaa agc ata gaa act ttt gct gtg act atc tgt gag   288
Phe Lys Gly Ile Lys Ser Ile Glu Thr Phe Ala Val Thr Ile Cys Glu
                85                  90                  95

cat ttc ctt tct tcc ttc aag cat gtc atc aga gct caa gtc tat gtg   336
His Phe Leu Ser Ser Phe Lys His Val Ile Arg Ala Gln Val Tyr Val
            100                 105                 110

gaa gaa gtt cct tgg aag cgt ttt gaa aag aat gga gtt aag cat gtc   384
Glu Glu Val Pro Trp Lys Arg Phe Glu Lys Asn Gly Val Lys His Val
        115                 120                 125

cat gca ttt att tat act cct act gga acg cac ttc tgt gag gtt gaa   432
His Ala Phe Ile Tyr Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu
    130                 135                 140

cag ata agg aat gga cct cca gtc att cat tct gga atc aaa gac cta   480
Gln Ile Arg Asn Gly Pro Pro Val Ile His Ser Gly Ile Lys Asp Leu
145                 150                 155                 160

aaa gtc ttg aaa aca acc cag tct ggc ttt gaa gga ttc atc aag gac   528
Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp
                165                 170                 175

cag ttc acc acc ctc cct gag gtg aag gac cgg tgc ttt gcc acc caa   576
Gln Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Gln
            180                 185                 190

gtg tac tgc aaa tgg cgc tac cac cag ggc aga gat gtg gac ttt gag   624
Val Tyr Cys Lys Trp Arg Tyr His Gln Gly Arg Asp Val Asp Phe Glu
        195                 200                 205

gcc acc tgg gac act gtt agg agc att gtc ctg cag aaa ttt gct ggg   672
Ala Thr Trp Asp Thr Val Arg Ser Ile Val Leu Gln Lys Phe Ala Gly
    210                 215                 220

ccc tat gac aaa ggc gag tac tcg ccc tct gtc cag aag aca ctc tat   720
Pro Tyr Asp Lys Gly Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr
225                 230                 235                 240

gac atc cag gtg ctc acc ctg ggc cag gtt cct gag ata gaa gat atg   768
Asp Ile Gln Val Leu Thr Leu Gly Gln Val Pro Glu Ile Glu Asp Met
                245                 250                 255

gaa atc agc ctg cca aat att cac tac tta aac ata gac atg tcc aaa   816
```

```
Glu Ile Ser Leu Pro Asn Ile His Tyr Leu Asn Ile Asp Met Ser Lys
            260                 265                 270

atg gga ctg atc aac aag gaa gag gtc ttg cta cct tta gac aat cca   864
Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro
        275                 280                 285

tat gga aaa att act ggt aca gtc aag agg aag ttg tct tca aga ctg   912
Tyr Gly Lys Ile Thr Gly Thr Val Lys Arg Lys Leu Ser Ser Arg Leu
    290                 295                 300

tga                                                               915

305
```

<210> 4
<211> 304
<212> PRT
<213> Artificial Sequence

<400> 4

```
Met Ala His Tyr Arg Asn Asp Tyr Lys Lys Asn Asp Glu Val Glu Phe
  1               5                  10                  15

Val Arg Thr Gly Tyr Gly Lys Asp Met Ile Lys Val Leu His Ile Gln
            20                  25                  30

Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln
        35                  40                  45

Leu Thr Leu Ser Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp
    50                  55                  60

Val Ile Pro Thr Asp Thr Ile Lys Asn Thr Val Asn Val Leu Ala Lys
65                  70                  75                  80

Phe Lys Gly Ile Lys Ser Ile Glu Thr Phe Ala Val Thr Ile Cys Glu
                85                  90                  95

His Phe Leu Ser Ser Phe Lys His Val Ile Arg Ala Gln Val Tyr Val
            100                 105                 110

Glu Glu Val Pro Trp Lys Arg Phe Glu Lys Asn Gly Val Lys His Val
        115                 120                 125

His Ala Phe Ile Tyr Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu
    130                 135                 140

Gln Ile Arg Asn Gly Pro Pro Val Ile His Ser Gly Ile Lys Asp Leu
145                 150                 155                 160

Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp
                165                 170                 175

Gln Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Gln
            180                 185                 190

Val Tyr Cys Lys Trp Arg Tyr His Gln Gly Arg Asp Val Asp Phe Glu
        195                 200                 205

Ala Thr Trp Asp Thr Val Arg Ser Ile Val Leu Gln Lys Phe Ala Gly
    210                 215                 220
```

Pro Tyr Asp Lys Gly Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr
225 230 235 240

Asp Ile Gln Val Leu Thr Leu Gly Gln Val Pro Glu Ile Glu Asp Met
245 250 255

Glu Ile Ser Leu Pro Asn Ile His Tyr Leu Asn Ile Asp Met Ser Lys
260 265 270

Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro
275 280 285

Tyr Gly Lys Ile Thr Gly Thr Val Lys Arg Lys Leu Ser Ser Arg Leu
290 295 300

<210> 5
<211> 304
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:baboon D3H

<400> 5
Met Ala His Tyr His Asn Asn Tyr Lys Lys Asn Asp Glu Leu Glu Phe
1 5 10 15

Val Arg Thr Gly Tyr Gly Lys Asp Met Val Lys Val Leu His Ile Gln
20 25 30

Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln
35 40 45

Leu Thr Leu Ser Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp
50 55 60

Ile Ile Pro Thr Asp Thr Ile Lys Asn Thr Val His Val Leu Ala Lys
65 70 75 80

Phe Lys Gly Ile Lys Ser Ile Glu Ala Phe Gly Val Asn Ile Cys Glu
85 90 95

Tyr Phe Leu Ser Ser Phe Asn His Val Ile Arg Ala Gln Val Tyr Val
100 105 110

Glu Glu Ile Pro Trp Lys Arg Leu Glu Lys Asn Gly Val Lys His Val
115 120 125

His Ala Phe Ile His Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu
130 135 140

Gln Leu Arg Ser Gly Pro Pro Val Ile His Ser Gly Ile Lys Asp Leu
145 150 155 160

Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp
165 170 175

Gln Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Gln
180 185 190

Val Tyr Cys Lys Trp Arg Tyr His Gln Cys Arg Asp Val Asp Phe Glu

195 200 205

Ala Thr Trp Gly Thr Ile Arg Asp Leu Val Leu Glu Lys Phe Ala Gly
210 215 220

Pro Tyr Asp Lys Gly Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr
225 230 235 240

Asp Ile Gln Val Leu Ser Leu Ser Arg Val Pro Glu Ile Glu Asp Met
245 250 255

Glu Ile Ser Leu Pro Asn Ile His Tyr Phe Asn Ile Asp Met Ser Lys
260 265 270

Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro
275 280 285

Tyr Gly Lys Ile Thr Gly Thr Val Lys Arg Lys Leu Ser Ser Arg Leu
290 295 300

<210> 6
<211> 304
<212> PRT
<213> baboon

<400> 6
Met Ala Asp Tyr His Asn Asn Tyr Lys Lys Asn Asp Glu Leu Glu Phe
1 5 10 15

Val Arg Thr Gly Tyr Gly Lys Asp Met Val Lys Val Leu His Ile Gln
20 25 30

Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln
35 40 45

Leu Thr Leu Ser Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp
50 55 60

Ile Ile Pro Thr Asp Thr Ile Lys Asn Thr Val His Val Leu Ala Lys
65 70 75 80

Phe Lys Gly Ile Lys Ser Ile Glu Ala Phe Gly Val Asn Ile Cys Glu
85 90 95

Tyr Phe Leu Ser Ser Phe Asn His Val Ile Arg Ala Gln Val Tyr Val
100 105 110

Glu Glu Ile Pro Trp Lys Arg Leu Glu Lys Asn Gly Val Lys His Val
115 120 125

His Ala Phe Ile His Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu
130 135 140

Gln Leu Arg Ser Gly Pro Pro Val Ile His Ser Gly Ile Lys Asp Leu
145 150 155 160

Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp
165 170 175

```
Gln Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Gln
            180                 185                 190

Val Tyr Cys Lys Trp Arg Tyr His Gln Cys Arg Asp Val Asp Phe Glu
        195                 200                 205

Ala Thr Trp Gly Thr Ile Arg Asp Leu Val Leu Glu Lys Phe Ala Gly
    210                 215                 220

Pro Tyr Asp Lys Gly Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr
225                 230                 235                 240

Asp Ile Gln Val Leu Ser Leu Ser Arg Val Pro Glu Ile Glu Asp Met
                245                 250                 255

Glu Ile Ser Leu Pro Asn Ile His Tyr Phe Asn Ile Asp Met Ser Lys
            260                 265                 270

Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro
        275                 280                 285

Tyr Gly Lys Ile Thr Gly Thr Val Lys Arg Lys Leu Ser Ser Arg Leu
    290                 295                 300
```

<210> 7
<211> 304
<212> PRT
<213> pig

<400> 7

```
Met Ala His Tyr Arg Asn Asp Tyr Lys Lys Asn Asp Glu Val Glu Phe
  1               5                  10                  15

Val Arg Thr Gly Tyr Gly Lys Asp Met Ile Lys Val Leu His Ile Gln
            20                  25                  30

Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln
        35                  40                  45

Leu Thr Leu Ser Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp
    50                  55                  60

Val Ile Pro Thr Asp Thr Ile Lys Asn Thr Val Asn Val Leu Ala Lys
65                  70                  75                  80

Phe Lys Gly Ile Lys Ser Ile Glu Thr Phe Ala Val Thr Ile Cys Glu
                85                  90                  95

His Phe Leu Ser Ser Phe Lys His Val Ile Arg Ala Gln Val Tyr Val
            100                 105                 110

Glu Glu Val Pro Trp Lys Arg Phe Glu Lys Asn Gly Val Lys His Val
        115                 120                 125

His Ala Phe Ile Tyr Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu
    130                 135                 140

Gln Ile Arg Asn Gly Pro Pro Val Ile His Ser Gly Ile Lys Asp Leu
145                 150                 155                 160
```

Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp
165 170 175

Gln Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Gln
180 185 190

Val Tyr Cys Lys Trp Arg Tyr His Gln Gly Arg Asp Val Asp Phe Glu
195 200 205

Ala Thr Trp Asp Thr Val Arg Ser Ile Val Leu Gln Lys Phe Ala Gly
210 215 220

Pro Tyr Asp Lys Gly Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr
225 230 235 240

Asp Ile Gln Val Leu Thr Leu Gly Gln Val Pro Glu Ile Glu Asp Met
245 250 255

Glu Ile Ser Leu Pro Asn Ile His Tyr Leu Asn Ile Asp Met Ser Lys
260 265 270

Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro
275 280 285

Tyr Gly Arg Ile Thr Gly Thr Val Lys Arg Lys Leu Thr Ser Arg Leu
290 295 300

<210> 8
<211> 298
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PBC amino truncated

<400> 8
Asp Tyr Lys Lys Asn Asp Glu Val Glu Phe Val Arg Thr Gly Tyr Gly
1 5 10 15

Lys Asp Met Ile Lys Val Leu His Ile Gln Arg Asp Gly Lys Tyr His
20 25 30

Ser Ile Lys Glu Val Ala Thr Ser Val Gln Leu Thr Leu Ser Ser Lys
35 40 45

Lys Asp Tyr Leu His Gly Asp Asn Ser Asp Val Ile Pro Thr Asp Thr
50 55 60

Ile Lys Asn Thr Val Asn Val Leu Ala Lys Phe Lys Gly Ile Lys Ser
65 70 75 80

Ile Glu Thr Phe Ala Val Thr Ile Cys Glu His Phe Leu Ser Ser Phe
85 90 95

Lys His Val Ile Arg Ala Gln Val Tyr Val Glu Glu Val Pro Trp Lys
100 105 110

Arg Phe Glu Lys Asn Gly Val Lys His Val His Ala Phe Ile Tyr Thr

```
        115                 120                 125

Pro Thr Gly Thr His Phe Cys Glu Val Glu Gln Ile Arg Asn Gly Pro
    130                 135                 140

Pro Val Ile His Ser Gly Ile Lys Asp Leu Lys Val Leu Lys Thr Thr
145                 150                 155                 160

Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp Gln Phe Thr Thr Leu Pro
                165                 170                 175

Glu Val Lys Asp Arg Cys Phe Ala Thr Gln Val Tyr Cys Lys Trp Arg
            180                 185                 190

Tyr His Gln Gly Arg Asp Val Asp Phe Glu Ala Thr Trp Asp Thr Val
        195                 200                 205

Arg Ser Ile Val Leu Gln Lys Phe Ala Gly Pro Tyr Asp Lys Gly Glu
    210                 215                 220

Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr Asp Ile Gln Val Leu Ser
225                 230                 235                 240

Leu Ser Arg Val Pro Glu Ile Glu Asp Met Glu Ile Ser Leu Pro Asn
                245                 250                 255

Ile His Tyr Phe Asn Ile Asp Met Ser Lys Met Gly Leu Ile Asn Lys
            260                 265                 270

Glu Glu Val Leu Leu Pro Leu Asp Asn Pro Tyr Gly Lys Ile Thr Gly
        275                 280                 285

Thr Val Lys Arg Lys Leu Ser Ser Arg Leu
    290                 295
```

<210> 9
<211> 301
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PBC carboxy truncated

```
<400> 9
Met Ala His Tyr Arg Asn Asp Tyr Lys Lys Asn Asp Glu Val Glu Phe
  1               5                  10                  15

Val Arg Thr Gly Tyr Gly Lys Asp Met Ile Lys Val Leu His Ile Gln
            20                  25                  30

Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln
        35                  40                  45

Leu Thr Leu Ser Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp
    50                  55                  60

Val Ile Pro Thr Asp Thr Ile Lys Asn Thr Val Asn Val Leu Ala Lys
65                  70                  75                  80

Phe Lys Gly Ile Lys Ser Ile Glu Thr Phe Ala Val Thr Ile Cys Glu
```

85 90 95

His Phe Leu Ser Ser Phe Lys His Val Ile Arg Ala Gln Val Tyr Val
100 105 110

Glu Glu Val Pro Trp Lys Arg Phe Glu Lys Asn Gly Val Lys His Val
115 120 125

His Ala Phe Ile Tyr Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu
130 135 140

Gln Ile Arg Asn Gly Pro Pro Val Ile His Ser Gly Ile Lys Asp Leu
145 150 155 160

Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp
165 170 175

Gln Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Gln
180 185 190

Val Tyr Cys Lys Trp Arg Tyr His Gln Gly Arg Asp Val Asp Phe Glu
195 200 205

Ala Thr Trp Asp Thr Val Arg Ser Ile Val Leu Gln Lys Phe Ala Gly
210 215 220

Pro Tyr Asp Lys Gly Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr
225 230 235 240

Asp Ile Gln Val Leu Ser Leu Ser Arg Val Pro Glu Ile Glu Asp Met
245 250 255

Glu Ile Ser Leu Pro Asn Ile His Tyr Phe Asn Ile Asp Met Ser Lys
260 265 270

Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro
275 280 285

Tyr Gly Lys Ile Thr Gly Thr Val Lys Arg Lys Leu Ser
290 295 300

<210> 10
<211> 298
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PKS carboxy truncated

<400> 10
Asp Tyr Lys Lys Asn Asp Glu Val Glu Phe Val Arg Thr Gly Tyr Gly
1 5 10 15

Lys Asp Met Ile Lys Val Leu His Ile Gln Arg Asp Gly Lys Tyr His
20 25 30

Ser Ile Lys Glu Val Ala Thr Ser Val Gln Leu Thr Leu Ser Ser Lys
35 40 45

Lys Asp Tyr Leu His Gly Asp Asn Ser Asp Val Ile Pro Thr Asp Thr

50 55 60

Ile Lys Asn Thr Val Asn Val Leu Ala Lys Phe Lys Gly Ile Lys Ser
65 70 75 80

Ile Glu Thr Phe Ala Val Thr Ile Cys Glu His Phe Leu Ser Ser Phe
85 90 95

Lys His Val Ile Arg Ala Gln Val Tyr Val Glu Glu Val Pro Trp Lys
100 105 110

Arg Phe Glu Lys Asn Gly Val Lys His Val His Ala Phe Ile Tyr Thr
115 120 125

Pro Thr Gly Thr His Phe Cys Glu Val Glu Gln Ile Arg Asn Gly Pro
130 135 140

Pro Val Ile His Ser Gly Ile Lys Asp Leu Lys Val Leu Lys Thr Thr
145 150 155 160

Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp Gln Phe Thr Thr Leu Pro
165 170 175

Glu Val Lys Asp Arg Cys Phe Ala Thr Gln Val Tyr Cys Lys Trp Arg
180 185 190

Tyr His Gln Gly Arg Asp Val Asp Phe Glu Ala Thr Trp Asp Thr Val
195 200 205

Arg Ser Ile Val Leu Gln Lys Phe Ala Gly Pro Tyr Asp Lys Gly Glu
210 215 220

Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr Asp Ile Gln Val Leu Thr
225 230 235 240

Leu Gly Gln Val Pro Glu Ile Glu Asp Met Glu Ile Ser Leu Pro Asn
245 250 255

Ile His Tyr Leu Asn Ile Asp Met Ser Lys Met Gly Leu Ile Asn Lys
260 265 270

Glu Glu Val Leu Leu Pro Leu Asp Asn Pro Tyr Gly Lys Ile Thr Gly
275 280 285

Thr Val Lys Arg Lys Leu Ser Ser Arg Leu
290 295

<210> 11
<211> 301
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PKS carboxy truncated

<400> 11
Met Ala His Tyr Arg Asn Asp Tyr Lys Lys Asn Asp Glu Val Glu Phe
1 5 10 15

Val Arg Thr Gly Tyr Gly Lys Asp Met Ile Lys Val Leu His Ile Gln
20 25 30

Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln
35 40 45

Leu Thr Leu Ser Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp
50 55 60

Val Ile Pro Thr Asp Thr Ile Lys Asn Thr Val Asn Val Leu Ala Lys
65 70 75 80

Phe Lys Gly Ile Lys Ser Ile Glu Thr Phe Ala Val Thr Ile Cys Glu
85 90 95

His Phe Leu Ser Ser Phe Lys His Val Ile Arg Ala Gln Val Tyr Val
100 105 110

Glu Glu Val Pro Trp Lys Arg Phe Glu Lys Asn Gly Val Lys His Val
115 120 125

His Ala Phe Ile Tyr Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu
130 135 140

Gln Ile Arg Asn Gly Pro Pro Val Ile His Ser Gly Ile Lys Asp Leu
145 150 155 160

Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp
165 170 175

Gln Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Gln
180 185 190

Val Tyr Cys Lys Trp Arg Tyr His Gln Gly Arg Asp Val Asp Phe Glu
195 200 205

Ala Thr Trp Asp Thr Val Arg Ser Ile Val Leu Gln Lys Phe Ala Gly
210 215 220

Pro Tyr Asp Lys Gly Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr
225 230 235 240

Asp Ile Gln Val Leu Thr Leu Gly Gln Val Pro Glu Ile Glu Asp Met
245 250 255

Glu Ile Ser Leu Pro Asn Ile His Tyr Leu Asn Ile Asp Met Ser Lys
260 265 270

Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro
275 280 285

Tyr Gly Lys Ile Thr Gly Thr Val Lys Arg Lys Leu Ser
290 295 300